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ELISA Enzyme linked immunosorbent assay. 
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FAB Fast atom bombardment. 
Fab Antibody binding fragment. 
Fc Antibody fragment which carries antibody effector functions. 
FPLC Fast protein liquid chromatography. 
G Guanosine. 
G Relative centrifugal force (only in the experimental sections). 
HAT Hypoxanthine, aminopterin and thymidine. 
HGPRT Hypoxanthine guanine phosphoribosyl transferase. 
Hchain Antibody heavy chain. 
HPLC High performance liquid chromatography. 
HRP Horse radish peroxidase. 




KA  Antibody affinity. 
ka Rate constant of association. 
kd  Rate constant of dissociation. 
Lchain Antibody light chain. 
MES N-Morpholinoethanesulphonic acid. 
MHC Major histocompatibility complex. 
mRNA Messenger RNA. 
MPD Methylpentanediol. 
NBD 7-Nitrobenzo-2-oxa-1,3-diazole. 
NBT Nitro blue tetrazolium. 
NAP Nucleic acid purification columns. 
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PBS Phosphate buffered saline. 
peep 3 ',5'-Bisphosphate of etheno-T-deoxycytidine. 
PEG Polyethylene glycol. 
pNPP Para-nitrophenyl phosphate. 
PI Isoelectric point. 
PVC Polyvinyl chloride. 
RIA Radioimmunoassay. 
roalkG Imidazole ring opened alkG. 
SDS Sodium dodecyl sulphate. 
ssDNA Single stranded DNA. 
dT 2'-deoxythymidine. 
TEA Triethylamine. 
TEMED N', N', N' N'-Tetramethylethylenediamine. 
THF Tetrahydrofuran. 
Tm Melting temperature. 
TMB 3 ,3',4,4'-Tetramethylbenzidine. 
VL Variable region on the light chain of an antibody molecule. 
V11 Variable region on the heavy chain of an antibody molecule. 
U Uridine. 
ABSTRACT 
Vinyl chloride, a widely used industrial precursor, is an established chemical 
carcinogen. It is metabolically activated to forms which alkylate DNA, producing a 
range of nucleic acid adducts. Resultant mutagenesis occurs almost exclusively at 
cytosines which are converted into the exocyclic lesion, 3,1V4-ethenodeoxycytidine 
A monoclonal antibody which specifically recognises cC has been developed. 
The specificity and affinity of this antibody has been determined by ELISA. 
Immunoaffinity gels have been prepared and an immunoenrichment procedure 
developed to detect and identify EC from normal nucleotides at very low abundance. 
Immunopurified samples of cC have been quantified by CZE on addition of a 
standard spike with a detection sensitivity of 1 cC in 108  normal nucleotides. Kinetic 
studies using this detection system found production of EC to be greater in single 
stranded DNA than in double stranded DNA when incubated with a metabolite of 
vinyl chloride. 
Oligonucleotides incorporating cC have been synthesised and used in 
thermodynamic and structural studies investigating the base-pairing effect of EC in 
double stranded DNA. EC was found to have a detrimental effect on duplex stability 
although the overall duplex structure was found to be undistorted. 
Oligonucleotides labelled with the dansyl group have been synthesised for 
use as gene probes. A monoclonal antibody with affinity to dansyl was developed to 
immunochemically detect this reporter group. Femtomole quantities of labelled probe 
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CHAPTER ONE 
Immunochemical, Thermodynamic and Structural Studies 
on the Mutagenic Lesion 3, M-ethenodeoxycytidine 
{IJJ1IIW1IOihi 
Cancer and Carcinogenesis 
Cancer is a dense, distorted, conglomeration of cells or tumour. Tumours 
develop from a single cell that has been freed from the normal constraints of cellular 
growth and proceeds to multiply without limits. If the growth is local and remains 
within the initial area, the tumour is said to be benign. However, tumours can become 
malignant by propagating outwards to multiple sites in the surrounding tissues and 
also to distant organs. Commonly death is due to this metastatis disrupting the 
functions of vital organs leading to irreversible damage'. 
As cell growth is central to tumour formation it follows that cells that multiply 
are more prone to become cancerous. Indeed, mature nerve cells do not multiply and 
are rarely sites of primary tumour formation. Conversely, cells in the skin, gut and 
bone marrow multiply continuously and often are the sites of initial tumours. Cells in 
the liver, thyroid and other glands multiply discontinuously and only in response to 
certain stimulii and are less commonly sites of initial tumour growth'. 
Two steps are required for the metamorphosis of a normal cell into one 
capable of tumour development. In an initiation step an agent affects a persistent but 
dormant cellular change and, after a period of latency, in a promotion step an 
additional agent induces uncontrolled cell propagation and tumour growth. UV light 
and some viruses and chemicals are recognised as initiation agents. Hormones, 
steroids and growth factors are promotors. 
The determinants which control cell number are cell division and cell death. 
These two factors provide the basis for the principal concepts which describe the 
carcinogenic modes of action of initiators and promotors at the cellular level: 
1) It is suggested that both initiators and promoters act on the reserve cell 
population known as stem cells. Stem cells are only stimulated to develop into 
growing, tissue specific cells under certain conditions. This perhaps accounts for the 
latent period in cancer development. These agents may modify the process of 
differentiation when stem cells move from dividing cells to non-invading, functioning 
cells by removing their controls on division, thus initiating tumourigenesis2. 
2) Necrosis and apoptosis describe the two processes of cellular death. 
Necrosis represents death by external agents which severely injure the cell. Apoptosis, 
or programmable cell death is an internally controlled mechanism whereby the cell 
commits suicide in response to a mild injury. Both initiators and promotors may 
trigger both forms of cell death but it has been suggested that they may have a more 
subtle inhibitory effect on apoptotic cell death. It is known that the p53 tumour 
suppressor gene monitors DNA damage and will induce apoptosis in irreparably 
damaged cells. If however, the p53 gene is damaged by the action of an initiator or 
promoting agent apoptosis is eliminated from the cell. Such a defect in programmable 
cell death may then lead to tumourigenesis3. 
As has been suggested, the origins of cancer may lie in initiators and 
promotors irreversibly changing heritable cellular characteristics at the molecular 
level. To effect such heritable changes, genetic modifications need to be made. This is 
the basic premise of the "Somatic Theory of Carcinogenesis" which states that 
initiators primarily interact with DeoxyriboNucleic Acid (DNA), the genetic 
macromolecule that stores the library of information for cellular growth and 
function  4. 
DNA 
DNA is a linear co-polymer composed of four monomeric, nucleoside 
subunits. The nucleosides are deoxyribose pentose sugar groups bearing 3-N-glycosyl 
bonds to heterocycles. In DNA the heterocycles are commonly the pyrimidines: 
cytosine and thymidine, and the purines: adenine and guanine. These nucleosides: 
deoxycytidine (dC), thymidine (T), deoxyadenosine (dA) and deoxyguanosine (dG) 
are coupled together by phosphodiester linkages forming strands of nucleic acid 
(figure 1). 
The overall tertiary, polymeric structure of DNA was determined by Watson 
and Crick to be a right handed double helix where two strands of nucleic acid run 
antiparallel to each other5. Watson and Crick proposed that forces holding the double 
helix together were generated from interstrand hydrogen bonds between heterocyclic 
base-pairings. Due to steric restrictions purines could only pair with pyrimidines. The 
base pairings were deduced from the probable tautomeric forms of the heterocycles. 
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Figure 2: Watson-Crick Base-Pairings 
cytosine generating three hydrogen bonds (figure 2)6.  This was confirmed in an 
observation made by Chargaff: the molar proportions of dA to T and dG to dC were 
approximately equal irrespective of the source of DNA7. This proposed model has 
now become established and it is known that the structure is stabilised not only by 
hydrogen bonds but also by 7t-orbital base-stacking, van der Waals and 
hydrophobic/hydrophilic interactions within the double helix8. 
The implications of the specific base-pairings led Watson and Crick to propose 
mechanisms whereby DNA could carry and store genetic information. They 
intuitively saw that as one strand is the complement of the other, the exact order of 
bases in one strand could be interpreted from knowing the base sequence of the other. 
This concept became the cornerstone of the "Central Dogma of Molecular Biology" 
which suggested DNA's role as a template that could be read and copied. The central 
dogma of molecular biology models the directional flow of genetic information and 
indicates the transfer pathways involved (figure 3)9•  What follows is an account of the 
5 
current knowledge of the processes involved in these transfer pathways and their role 





Figure 3: The Transfer Pathways in the Central Dogma of Molecular Biology 
The DNA bases represent the four letters of the genetic code: A, T, C and G. 
These letters are organised within a specific reading frame as triplets or codons thus 
64(4 3)  combinations are possible. Each codon represents an amino acid and a gene is 
the series of codons encoding the amino acid sequence of a protein. The precise order 
of amino acids determines how the protein will fold and hence operate. Thus the 
sequence of nucleotides in DNA ultimately contols protein structure and function. 
There are 20 amino acids and although codons are specific for one amino acid they are 
degenerate as some amino acids are associated with more than one codon. 
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Figure 4: Ribonucleic Acid 
There is an intermediary step in the process of translating the four letter DNA 
code into the 20 letter protein-amino acid code. This involves RiboNucleic Acid 
(RNA). Enzymes unravel the double helix and using one strand as a template, 
synthesise the complementary sequence with the four ribonucleotides: adenosine (A), 
cytidine (C), guanosine (G) and uridine (U), uridine replaces T in RNA (figure 4). 
This process known as transcription, creates a new template called messenger RNA 
(mRNA) which is translated distant from DNA at ribosomes into amino acid 
sequences which are folded into proteins. 
Gene expression is controlled by regulatory proteins that bind to regions of 
DNA that promote mRNA synthesis. These proteins can therefore repress synthesis of 
the gene product. Repressor proteins are also gene products capable of being 
repressed. Thus expression of a single gene can be subject to a complex system of 
interacting feedback mechanisms (figure 5). 
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Figure 5: Gene Expression and Repression 
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Before cells can divide and multiply they must undergo mitosis which 
duplicates the cellular nucleus. A requirement for mitosis is replication of DNA. To 
preserve the integrity of genetic information replication must be extremely precise. 
However, the entire human genetic database or genome consists of approximately 
3x109 base-pairs. The speedy duplication of such a large amount of material with high 
fidelity is a huge undertaking and it is inevitable that mistakes occur. The replicative 
process has been well studied in the bacterial strain, Escherichia coli (E. coil) which 
has a smaller genome of approximately 5x106 base-pairs. The replication rate in E. 
coil is 250-1000 nucleotides per second yet, despite this high copying velocity, 
mispaired bases occur only once in every i09 to 1010  nucleotides ie. one error every 
iO3 to 104 copies. 
A large battery of enzymes is responsible for this achievement. DNA 
polymerases are the enzymes that synthesise DNA. They insert nucleotides using 
Watson-Crick base-pairings between opposing bases along the template strand. 
However, other base-pairings are thermodynamically and sterically feasible. This 
would potentially result in an error rate of one in 10 to 10 nucleotides but 
polymerases have an inbuilt error-checking capability which recognises such 
mismatches, inhibiting further chain elongation until the aberrant nucleotide has been 
removed and the correct base inserted. This ability to correct mistakes results in one 
erroneous base every 106  to 10 8  nucleotides. The fidelity of DNA replication is further 
increased 102  to iø fold by mismatch repair enzymes. These enzymes proof-read 
DNA and recognise mismatched bases causing excision of the DNA strand section 
containing the mispaired base and resynthesis of that segment in the daughter strand. 
Once a newly synthesised DNA strand has been proof-read it is methylated at the A'6-
postion on deoxyadenosines (in mammalian DNA the C5-postion on deoxycytosines is 
methylated) enabling mismatch repair enzymes to distinguish between parent and 
daughter strands. 
The Molecular Basis of Carcinogenesis 
The structural integrity of DNA is crucial to cellular function. However, 
despite this, DNA is in a state of constant flux. DNA is chemically reactive and can 
undergo a variety of reactions which change the covalent structure. Any structural 
9 
modification can potentially lead to alterations in the genetic code and how it is read. 
Such changes are termed mutations and there are three broad classes of mutation: 
point mutations, 
frame shift mutations, 
large scale rearrangement mutations. 
Point mutations are single base changes in the genetic code. During replication 
they occur either as transitions where a purine is replaced by another purine or a 
pyrimidine is replaced by another pyrimidine or transversions where purine is 
replaced by pyrimidine or vice versa. Of the three types of mutational event, point 
mutations have the least effect as only one codon is changed per point mutation. They 
may even be "silent" due to the degeneracy of the genetic code when the altered 
codon still codes for the same amino acid. 
Frame shift mutations occur when bases are added or removed. This results in 
a complete change in the way the gene is read as it alters the reading frame. This type 
of mutation can have a devastating effect on amino acid sequence and hence protein 
structure usually resulting in a "nonsense protein". 
Large sequences of DNA can be deleted, inverted or transfered from one 
genomic region to another. Such large scale rearrangements can affect a number of 
genes. 
Mutations can result in carcinogenesis when the gene responsible for a 
biological process is partially or completely defective. Many genes have specific 
regions or "hot spots" that are susceptible to mutational events. Mutational agents 
often have their own, widely different spectrum of hot spots within a gene. After a 
mutation the faulty gene products either operate as normal, operate with decreased 
efficiency, cease to operate at all or have an altered function. The consequences of this 
are entirely dependent on the nature of the protein involved. Usually the result is 
detrimental to the survival of the cell and leads to cell death. However, it can on 
occasion promote cellular growth and carcinogenesis. 
The origins of frame shift and large scale rearrangement mutations are 
speculative and more is known about point mutations. Point mutations occur when 
non-Watson-Crick base-pairing has escaped the error checking and proof reading 
phases of replication or as the result of DNA damage. 
10 
DNA is damaged by endogenous or exogeneous genotoxic agents. 
Endogenous DNA damage arises from normal cellular, environmental conditions and 
metabolic processes. Commonly, dC and dA are deaminated, dG and dA depurinated 
and dC and T depyrimidated by hydrolysis in the aqueous medium. In addition, highly 
reactive chemical species can be released during cellular metabolism which can 
oxidise and alkylate DNA generating modified adducts. Exogeneous genotoxins 
include radiation, viral cells and a wide spectrum of chemicals. To cope with such 
continual change in their DNA, cells have developed a large range of repair systems to 
limit spontaneous or induced damage and maintain the genetic code. 
Chemicals possess carcinogenic properties by covalently binding to or reacting 
with DNA thus creating mutagenic lesions. Ultimate carcinogens are those chemicals 
which act directly with DNA. Some chemicals, known as precarcinogens, require 
transformation into an activated form. This can occur spontaneously but often requires 
activation via an enzymatic pathway and can involve a number of intermediate steps. 
DNA is a nucleophilic target and therefore ultimate carcinogens are often 
electrophiles. 
Vinyl Chloride 
Vinyl chloride is an important industrial precursor, used in huge quantities for 
the manufacture of polyvinyl chloride (PVC) and other polymers. During the early 
1970s toxicological experiments investigating the long term effects of this chemical in 
mammals reported tumour formation in rats exposed to vinyl chloride contaminated 
air13. Subsequent studies found vinyl chloride also induced cancer when administered 
to mice and hamsters 14,15.  By the mid-1970s a high incidence of liver angiosarcoma 
(blood vessel derived tumours) among workers involved in vinyl chloride 
16 manufacture was noted and 	 Thereafter, two epidemiological studies 
revealed an increased incidence of malignant tumours of the skin, lung, colon and 
thyroid in industrially exposed employees'7'18. It was also noted that the frequency of 
chromosomal aberrations was higher in these workers compared to unexposed 
people'92o 
The mutagenic properties of vinyl chloride were examined in bacterial 
systems. It was found to induce a high spontaneous mutation rate in E. coli21, 
11 
Schizosaccharomyces pombe and Saccharomyces cerevisiae22 but only in systems 
supplemented with microsomal enzyme activity. The requirement for microsomal 
enzyme activity suggested that vinyl chloride was not a direct mutagen but a 
precarcinogen that required prior metabolic activation before any mutagenic effect 
could be observed. The mono-oxygenase enzymes in microsomes were presumed to 
be responsible for this metabolic activtion in vinyl chloride induced mutagenesis. In 
vitro studies using radiolabelled vinyl chloride revealed high levels of covalent 
binding of the putative metabolic product to cellular proteins with substantially lower 
levels of binding to DNA. This observation was rationalised by a proposed 
mechanism whereby vinyl chloride was metabolically activated by cytochrome P450 
mediated monooxygenases present in microsomes to form the reactive metabolite 
chloroethylene oxide (CEO). CEO then spontaneously rearranges to a less reactive 
compound, chloroacetaldehyde (CAA) (figure 6). CAA was thought to be responsible 
for the predominant protein adduction and CEO to be solely responsible for DNA 
binding23. 
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Figure 6: Metabolic Activation of Vinyl Chloride to CEO and CAA 
The presence of both compounds was established when vinyl chloride was 
passed through mouse liver microsomes in the presence of oxygen and both volatile 
metabolites, CEO and CAA were trapped by reaction with 4-(4-nitrobenzyl) 
pyridine 14.  The half-life of CEO due to rearrangement into CAA was calculated at 1.6 
minutes in aqueous solution from kinetic experiments23. Vinyl chloride metabolism 
has since been found to be entirely dependent on cytochrome P450 oxidation and as 
such obeys first order kinetics before enzyme saturation occurs at high dose levels25'26. 
Tumour formation has been directly correlated to the concentration of vinyl chloride 
exposed to rats at first order kinetic levels27. 
Evidence for the identity of the ultimate carcinogen was provided by feeding 
experiments to probe the in vivo modes of action of CEO and CAA. 2,2'-Bis(2-
chioroethyl) ether and chloroethanol are also metabolised to form CAA but by 
12 
pathways other than via a CEO intermediate. 2,2'-dichlorodiethyl ether is oxidised by 
cytochrome P450 to CAA and chioroethanol which is in turn metabolised to CAA by 
alcohol dehydrogenase. When groups of rats were exposed to 2,2'-dichlorodiethyl 
ether, chioroethanol and vinyl chloride only the last group developed tumours. On 
analysis of the rat livers only those rats administered with vinyl chloride showed 
significant DNA binding28. In corroberation with these findings CEO was found to be 
mutagenic in Salmonella lyphimurium29 and carcinogenic in mice30. Contrary to this 
conclusion subsequent tests found CAA to be mutagenic in strains of Salmonella 31 
and Aspergillus nidulans32 and carcinogenic in mice33. It is now presumed that both 
CEO and CAA alkylate DNA in vivo but to different extents and with a different 
pattern of DNA adducts. CAA is further metabolised combining with glutathione via 
glutathione transferase before urinary excretion16 (figure 7). 
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Figure 8: Vinyl Chloride, CEO and CAA Induced DNA Adducts 
The identity of the alkylated DNA adducts formed from vinyl chloride 
exposure was established both by in vivo and in vitro experiments using radiolabelled 
vinyl chloride. 1,1V6-ethenodeoxyadenosine (EA), 3,N4-ethenodeoxycytidine (cC) and 
N7-(2-oxoethyl) deoxyguanosine (oeG) were readily formed upon in vitro incubation 
of DNA and rat liver microsomes with '4C-labelled vinyl chloride34. However, only 
oeG was formed under non-denaturing conditions and in far greater abundance 
relative to the etheno adducts. When 14C-labelled vinyl chloride was administered to 
rats only oeG was detected at low dose levels but at higher doses EA, EC and a further 
234 
adduct were detected. This was identified as N ,3-ethenodeoxyguanosine (cG1) 
14 
When DNA and RNA were incubated with CAA in vitro EA, FC, oeG, G1 and a fifth 
adduct assigned as 1 ,N2-ethenodeoxyguanosine (EG2) were formed 34  (figure 8). 
Inter-strand crosslinking was also found between dA residues in poly d(AT) 
duplexes treated with CAA34. Although this would have significant biological effects 
crosslinking has not been observed in any in vivo experiments. 
In vitro experiments had suggested that the formation of the etheno adducts is 
specific to single stranded regions of DNA. The amino and imino groups involved in 
formation of the etheno bridge are involved in hydrogen bonding interactions within 
double stranded DNA. They are therefore electronically deactivated and sterically 
protected within the double helix. It is also been observed that such chemical 
modifications are sensitive to intrastrand base-stacking interactions. Formation of oeG 
is due to alkylation by CEO and is observed in both single and double stranded 
regions of DNA. This is a result of the accessibility of the N7 position of dG in the 
major groove of duplex DNA35. 
The specific mechanism of DNA alkylation by CEO and CAA to form the 
etheno adducts was elucidated from direct observation of reaction intermediates by 
FTNMR and GCMS (figure 9). Initially nucleophilic attack by the imino nitrogen 
displaces chloride from the alkylating agent in a concerted process. This is of SN2 
type during reaction with CAA but the less hindered epoxide carbon is probably 
attacked in CEO with chloride displacement. This is followed by nucleophilic attack 
from the exocyclic amino group in close proximity to form a cyclic hydrate 
intermediate. These are isolateable compounds under physiological conditions with 
half-lives of 1.4 and 13 hours for the hydrated etheno forms of dA and dC 
respectively. The energetically-favourable planar, resonance-stabilised ring system 
formed by loss of water pushes the reaction forward to the formation of the etheno 
bridge system. Evidence that nucleophilic attack is by the imine nitrogen first then the 
amine nitrogen was provided from experiments involving the analogue N3-methyl 
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Figure 9: The Mechanism of CEO and CAA Alkylation of DNA to Form Etheno 
Adducts 
Vinyl chloride is not the only source of these adducts. Vinyl bromide is 
recognised to behave similarly to vinyl chloride as it is metabolised to bromoethylene 
oxide and bromoacetaldehyde26. The industrial chemicals 1 ,2-dichloroethane and 
chloroethanol are both metabolised in mammals to chloroacetic acid via CAA31. CAA 
16 
is also an industrially used chemical and has been identified as a contaminant in 
drinking water due to chlorination of humic substances33. Vinyl carbamate epoxide, a 
structurally similar compound to CEO is produced by mammalian metabolism of the 
industrial polymer materials ethylcarbamate (urethane) and vinyl carbamate (figure 
10). This compound was found to be a highly potent mutagen and carcinogen, 
forming the same spectrum of DNA adducts as vinyl chloride37. It is thought that 
these adducts are also formed endogenously as well as by exogeneous chemicals. EA, 
cC and cG1 have been identified in the livers, lungs and kidneys of animals unexposed 
to exogeneous sources38. In these cases the DNA reactive species are presumed to be 
by-products originating from lipid peroxidation processes. These are known to 
produce highly reactive alkenes and aldehydes which can react with DNA directly 39  or 
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Figure 10: The Metabolic Activation of Ethyl Carbamate and Vinyl Carbamate 
The Molecular Biological Consequences of CEO and CAA Modified DNA 
CEO and CAA are known to inhibit DNA synthesis in mammalian cells. The 
inhibitory effect is not directed at nucleotide biosynthesis but directly on the DNA 
replication machinery as DNA alkylation by these chemicals disrupts DNA 
polymerase and other enzymes41. This has been directly attributed to the DNA adducts 
formed and their properties have been studied. 
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1) cA: The etheno bridge in EA blocks both the hydrogen bonding sites of dA. 
These sites are crucial to Watson-Crick base-pairing of dA with T. Their 
unavailability will affect transcription and replication. Therefore SA is potentially a 
promutagenic lesion. 
It has been demonstrated that cA does possess a miscoding effect on in vitro 
RNA and DNA synthesis. Poly dA templates modified with CAA were shown to 
induce errors in transcription by E. coli DNA dependant RNA polymerase. This 
enzyme incorporated a range of nucleotides opposite cA in the newly synthesised 
strand with insertion of A favoured to the biologically correct U42. C was also a minor 
incorporation product42. Studies using similarly treated poly dA templates showed the 
replicative fidelity of E. coli DNA polymerase I was also corrupted. This enzyme 
incorporated dG opposite cA in the complementary strand but with poor miscoding 
efficiency with only one mispair occuring in every 60-550 EA adducts43'44. This 
represents a dA.dT to dC.dG type of transvertion point mutation. These studies also 
reported a significant reduction in the rate of primer elongation along the modified 
template with stops occuring at cA residues. Paradoxically in vivo mutagenesis by cA 
has never been established. It is proposed that error-free bypass of EA by polymerase 
results from an unknown, favoured configuration of cA templating for T reducing the 
mutagenic efficiency45. 
Structural and thermodynamic studies have not supported this hypothesis. 
Results from NMR studies on cA containing duplexes have found that although T can 
be incorporated opposite FA with little disruption of the double helix, no inter-base 
hydrogen bonding is formed 46  (figure 11). This makes it extremely unlikely that cA 
can template for T. The converse is true for base-pairing between EA and dG which 
can form two hydrogen bonds when cA is rotated into a syn-configuration47 (figure 
11). This is supported by a crystal structure which also shows dG pairing with EA in a 
syn-configuration and thermodynamic data which indicate the cA.dG base-pairing to 
be the most stable base-pairing possible 48. 
The lack of in vivo evidence for EA coding for dG possibly indicates that this 
mutagenic lesion is a substrate for a repair enzyme which can effectively remove CA 
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Figure 11: T(anti):LA(anti) and dG(anti):cA(syn) Base-Pairings 
2) EC: The etheno bridge in EC blocks two of the three hydrogen bonding sites 
of dC. In this way the genetically correct base-pairing of EC with dG is destabilised 
which could possibly induce errors in transcriptional and replicative processes. 
Therefore cC is also a potential promutagnic lesion. 
cC does demonstrate miscoding properties on in vitro RNA and DNA 
synthesis. CAA modification of poly dC templates can cause E. coli42 and calf 
thymus 49  DNA dependent RNA polymerases to transcribe with ambiguity. These 
enzymes incorporate U or A opposite cC during transcription. This base-pairing 
ambiguity is also demonstrated during replication. Errors are induced on E. coli DNA 
polymerase I by CAA modified poly dC 43  and poly d(CG)44  templates. Both dA and T 
are incorporated opposite cC, with incorporation of dA being slightly favoured. A 
higher miscoding efficiency is observed relative to EA as one cC.dA mispair occurs 
every 30 cC and every 80 cC for a cC.T mispair44. 
Due to the ambiguous coding nature of EC it has been described as a non-
instructural mutagenic lesion as it allows replication past the lesion site but does not 
direct incorporation of a specific base. A more detailed study of the miscoding 
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properties examined the base incorporation and primer extension at a site specific cC 
by E. coli DNA polymerase I Kienow fragment50. Kienow fragment is E. coli DNA 
polymerase I minus 5'-to-3' exonuclease activity. However, the enzyme used in this 
mutagenesis study was also devoid of the 3'-to-5' exonuclease proof reading 
capability. It revealed that although misinsertion of dA opposite cC is favoured over 
T, chain extension occurs more readily when T is paired with cC. In this way cC can 
be responsible for both dC.dG to dT.dA transition and dC.dG to dA.dT transversion 
point mutations. 
In vivo studies using DNA which was treated in vitro with CAA and 
transfected into E. coli suggested that mutagenesis occurs almost exclusively at dCs. 
Of the mutations targeted at dCs 80% were dC to dT transitions and 20% were dC to 
dA transversions45. This indicates that although cC is an non-instructional lesion it has 
some miscoding bias where dA is preferentially inserted in 4 out of every 5 
misinsertion events attributable to cC. This observation has not yet been rationalised 
but it may be that insertion of either base is sequence dependent. 
It is commonly believed that other non-instructional lesions such as abasic 
sites and bulky lesions cause polymerases preferentially to insert dA opposite the 
lesion site. In this respect cC lesions follow this "adenine rule". The mechanism for 
the "adenine rule" whereby dA is preferentially inserted is thought to include SOS 
functions. SOS functions are induced by events that halt normal polymerase 
replication and bulky DNA lesions are known to cause such stops in replication. To 
continue DNA synthesis past the lesion site, SOS functions provide a mechanism for 
base-pairing at the lesion and translesional synthesis. The base-pairing is often 
insertion of dA and is therefore error prone. However, when cells transfected with 
CAA modified templates were irradiated with UV light, which also induces SOS 
functions, no change in the specificity of base mutations at dC was observed. As an 
alteration in mutations would be expected on UV irradiation it was concluded that 
unlike all other known non-instructional lesions cC mutagenesis is independent of 
SOS functions51. Further experimental evidence supporting this view was obtained by 
using the mutant E. coli strains, recA and recK. They were transfected with a 
oligonucleotide template bearing a site specific cC and mutagenesis in progeny 
plaques examined at this position. The recA gene product is an integral protein in SOS 
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mechanisms for error prone repair and as such is required for mutagenesis at 
"classical" non-instructional lesions. It was found that neither the survival nor the 
mutational efficiency in either recA+  or recA cells was significantly different. The 
conclusion from these findings is that EC represents a previously undiscovered class 
of mutagenic lesion that is non-instructional but allows DNA synthesis at and past the 
lesion site without invoking SOS responses52. The mutagenic frequency was measured 
at the site specific EC in both cell strains and found to be approximately 30% which 
represents a high mutational efficiency 52. 
Base-pairings for both the cC.dA and sC.T mismatches have been proposed 
that include hydrogen bond formation 53  (figure 12). However, no structural 















HO 	 N 	OH 
cc 	 OH 
OH 	 NN 
H 
Figure 12: Proposed T(anti):cC(anti) and cC(anti):dA(syn) Base Pairings 
3) oeG: The N7 position of dG takes no part in normal Watson-Crick base 
pairing and therefore oeG would be expected to retain base-pairing capabilities with 
dC. The additional alkyl group may however, inhibit the binding of DNA regulatory 
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proteins. Promutagenic properties for oeG have been proposed based on an expected 
hemiacetal isomer of oeG. This isomer, in equilibrium with dG could code 
analogously to dA and therefore base-pair with T (figure 13). Although this model is 
plausible no evidence for any in vitro miscoding properties has been demonstrated in 
experiments using poly d(GC) templates treated with CEO and E. coli DNA 













Figure 13: Proposed Isomerisation of oeG 
4) FG, and cG2: Of the two ethenodeoxyguanosine adducts found on in vitro 
treatment of DNA with CAA, only cG1 has been found in vivo. cG1 has been found to 
be mutagenic in both in vitro and in vivo assays. Unlike EC it induces monospecific 
base changes. In vitro experiments demonstrated 8G1 miscoding for T with a 
mutagenic frequency of 20% during reverse transcription of RNA templates treated 
with CAA55. Consistent with this report were in vivo assays in E. coli that illustrated 
site specific 6G1 lesions producing dG to dA transitions with a mutagenic frequency 
of 13%56. 
Enzymatic Repair of Etheno Adducts 
To maintain the integrity of their genomic DNA, cells have developed 
enzymes to repair the DNA lesions produced by DNA damaging agents. Studies on 
DNA repair mechanisms have classified DNA repair into three broad categories 57: 
1) Incision-excision repair: Enzymes nick phosphodiester bonds to produce 
breaks in the strand containing the lesion. The segment of oligonucleotide containing 
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the lesion is then removed along from the cleavage site. Enzymes resume DNA 
synthesis and the double strand is reconstructed and ligated. 
DNA N-glycosylase repair: Aberrant DNA bases are recognised by 
enzymes and removed by cleavage of the N-glycosyl bond to leave apurinic or 
apyrimidinic sites. These are then repaired by the incision-excision mechanism. 
Transferase repair: The original identity of the DNA base is restored after 
removal of the adduct functionality by an enzyme. 
To determine whether DNA repair systems mediate mutagenesis induced by 
etheno adducts the metabolism of vinyl chloride adducts was examined. Rats were 
exposed to vinyl chloride for a five day period and the levels of DNA adducts present 
in the liver, lungs and kidney measured at 3, 7 and 14 days post-exposure. It was 
found that all the vinyl chloride induced adducts were highly persistent in these 
tissues and half lives of oeG and cG1 were calculated at 62 hours and 30 days 
respectively while cC and cA were even more persistent58. These results seem to 
indicate that no effective repair system for the removal of these adducts, particularly 
the etheno bases exists. 
Contrary to this evidence were in vitro experiments which demonstrated that 
when CAA modified DNA was treated with rat brain tumour cell-free homogenates 
ethenoguanine and ethenoadenine were released 59. This indicated the presence of 
specific N-glycosylases which could cleave these adducts from DNA. Subsequently it 
was found that ethenoguanine could be released from CAA treated DNA by the 3-
methyladenine DNA glycosylase II repair enzyme isolated from E. coli. The specific 
enzyme activity for ethenoguanine release was 20 fold lower than that of 3-
methyladenine but was at levels that would still effectively mediate cG1 induced 
mutagenesis60. It has also been discovered that a human N-methylpurine DNA 
glycosylase cloned into E. coli has a 10 fold substrate preference for EA relative to 3-
methyladenosine which was originally thought to be the primary enzymatic 
substrate61. The substrate specificity of this enzyme was explored further and was 
found to release all the etheno adducts induced by vinyl chloride. The rate of adduct 
release by this glycosylase was substrate dependent with release of FA and EC 
occuring at similar rates while cG1 was released 5 times slower 62. 
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The existence of such repair capacities in cells obviously mediates the 
mutagenic effects of these etheno adducts. The evolution of such repair enzymes also 
supports the proposal that these adducts are formed endogenously as well as by 
exogeneous chemicals. 
Antibodies 
Antibodies have been used as biochemical tools to monitor the formation and 
metabolism of DNA adducts. 
Antibodies are a class of serum proteins that are induced by the host's immune 
defence mechanism on recognition of a foreign body. In general, antibodies are 
symmetrical molecules comprised of four peptides. Two identical glycosylated heavy 
chains of 50,000 to 70,000 Daltons and two identical non-glycosylated light chains of 
approximately 25,000 Daltons. These peptides are held together covalently by 
















Antigen Binding Sites 
Figure 14: Diagramatic Representation of an IgG Antibody Molecule 
Antibodies are grouped into 5 main classes which distinguish their structural 
and biological properties: IgA, IgD, IgE, IgG and 1gM. The IgG class is the 
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predominant serum isotype and is subdivided into 4 subclasses in mice: IgG1, IgG2 , 
IgG2b and IgG3. Both the light and heavy chains are made up of homology units of 
approximately 110 amino acid residues which are folded into regions called domains. 
The class and subclass of an antibody can be determined by examination of the amino 
acid sequences of the light and heavy chain domains. Both have sections of amino 
acid sequence homology known as constant regions. These show little variation in 
antibody molecules of the same class and subclass. They are designated CL  and CH,, 
for the light and heavy chains respectively where x=1 to 3 for the heavy chain domain 
number. There are also light and heavy chain domains of considerable sequence 
variability designated VL  and VH. These domains create the antigen binding sites. 
Antibody molecules can be pictorially represented as "Y" shaped molecules 
with the antigen binding sites at the ends of the "arms". These arms are known as the 
Fab regions and the "body" which provides the antibody effector functions is known 
as the Fc region (figure 14). 
The binding between antibody and antigen is created by coulombic forces 
including electrostatic, van der Waals and hydrophobic interactions as well as 
hydrogen bonding. Binding specificity and affinity directly result from the structural 
and electrostatic complementarity of the antigen and antigen binding site. Antigen 
binding sites are extremely specific. However, cross-reaction can occur if antigens are 
structurally related. Antibody-antigen affinities typically range from 10 to 1010  M' 
and are dependent on the rates of association and dissociation between antibody and 
antigen according to the equation: 
KA = kjkd = [Ab.Ag]I[Ab].[Ag] 
where KA  is the antibody (Ab) affinity to the antigen (Ag), 
ka  is the rate of association, 
kd is the rate of dissociation, 
[Ab.Ag] is the concentration of antibody-antigen complex, 
[Ab] is the concentration of free antibody, 
[Ag] is the concentration of free antigen at equilibrium. The rate of association 
is limited by solution diffusion but also the time spent by the antigenic determinant or 
binding region in the conformation recognised by the antibody. The rate of 
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dissociation is dependent on the strength of the bonds formed between the antibody 
and antigen63. 
Immunoaffinity Chromatography 
The specificity of antibodies has been exploited to isolate biological material. 
Immunoaffinity chromatography uses the specific but reversible binding between an 
antigen and an antibody bound to a solid phase support64. The method can be used to 
purify natural substances from contaminating constituents in biological samples but 



















I 	AminoalkylI 	 AbNH2 
d) OCN 	 ONH(CH2)xNH2 
Diimide 














NNH CO2H  He) 	 H 	
rONH^\,/KN/HkN/\CO2H 
SH 	 SSAb 
2HH2 I 	





NHNH2 	I 	NHNHAb 
Figure 15: Solid Phase Coupling Chemistries: a) Cyanogen Bromide, b) 
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Activated Agarose 
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The immobilisation support is usually agarose based but many different 
coupling chemistries have been used for antibody attachment to the solid phase. The 
agarose based solid support provides hydroxyl groups which are functionalised to 
become reactive with the amino acid residues on the antibody. The antibody can also 
be functionalised often by oxidation of vicinal diol groups on the carbohydrate 
residues (figure 15)64-67 
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Figure 16: Immunoaffinity Chromatography Stages: a) Loading, b) Washing, c) 
Eluting and d) Regenerating 
The principal stages involved in immunoaffinity chromatography are: 
Loading: the crude sample is applied to the column and the desired product 
allowed to bind to the immobilised antibodies. 
Washing: the column is washed to remove the contaminating impurities. 
Eluting: the desired product is eluted from the column with a buffer that 
reduces the antibody affinity to the antigen. 
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Regeneration: the column is prepared for further use, removing the elution 
buffer by washing 64  (figure 16). The sample and washing buffers used are usually 
around physiological pH and salt concentration. However, many different eluting 
conditions have been used. After removal of any contaminating substances the desired 
product must be desorbed. This must break the antibody-antigen interactions but leave 
the antibody sufficiently intact to enable reuse of the column. Elution buffers can 
reduce the antigen-antibody interactions by a number of different mechanisms: 
Antibody denaturing: high concentrations of guanidine.HCI or urea or 
extremes of pH will denature antibodies. 
Disruption of hydrogen bonding and coulombic interactions: chaotrophic 
ions disrupt hydrogen bonds. They can be arranged in order of chaotrophicity: Cl_ < I- 
< C104 104 <CF3CO2 <SCW < CC13CO2 . 
Disruption of hydrophobic interactions: organic solvents such as 
acetonitrile, methanol, ethanol, dioxane and ethylene glycol have been used in 
aqueous solutions to reduce buffer polarity and hence hydrophobic interactions. 
linmunoaffinity chromatography has been widely used for the successful 
isolation and concentration of many biological materials such as proteins, peptides, 
nucleic acids, cofactors, steroids, hormones and cells. 
Antibodies to Carcinogen-DNA Adducts 
As antibodies had been successfully raised to naturally occurring nucleosides 
and nucleic acids 69  immunological methods have been employed in the detection and 
analysis of carcinogen-DNA adducts. Initially antibodies were raised to the bulkier 
DNA 	adducts 	such 	as 	N2-[ 1 O-(7 ,8a-trihydroxy-7,8,9, 10- 
tetrahydrobenzo[a]pyrene)yl]dG 	(figure 	17a), 	2-(7-dG)-2,3-dihydro-3- 
hydroxyalfatoxin B1 (figure 17b) and 3-[N-(dG-N2-yl)]acetamidofluorene (figure 17c). 
The antibodies were used in immunoassays for the detection and quantification of 













Figure 17: Bulky DNA Adducts 
Later it was found that nucleosides structurally altered with even very small alkyl 
modifications such as methyl (figure 18a) or ethyl (figure 18b) groups could be 
recognised by antibodies even in the presence of large excesses of unmodified 
nucleosides 71.  These antibodies have been used to detect carcinogen-DNA adducts 






Figure 18: Small DNA Adducts 
enzyme linked immunosorbent assay (ELISA), immunoslot-blots and 
immunoelectromicroscopy or to clean-up and concentrate carcinogen-DNA adduct 
samples prior to analysis71. Detection limits vary but it has been possible to detect as 
little as attomole concentrations of carcinogen-DNA adducts72. 
Biomonitoring of Etheno Adduct Levels 
In model studies exposing rats to vinyl chloride, tumour incidence correlated 
well with etheno adduct level73. Methods of etheno adduct detection have been 
investigated to effectively monitor the formation of these adducts in biological 
samples. This could facilitate the creation of effective risk assessment models for 
human exposure to the chemicals that induce these adducts and the potential for 
carcinogenesis. Due to the extremely low levels of DNA adducts present in vivo, 
highly sensitive analytical techniques must be employed. 
Many methods to achieve effective biomonitoring have been reported with 
varying degrees of sensitivity of adduct detection. Initially rats were exposed to [1,2-
'4C] labelled vinyl chloride. The liver DNA was extracted, enzymatically hydrolysed 
and the adducts separated by HPLC before scintillation counting to quantify the 
adduct levels 73.  The fluorescent properties of the etheno bases especially 8A and cG 
have been used in on-line fluorescent detection of HPLC eluents74. The sensitivity of 
detection using this method was highest for EA, detecting levels of 1 picomole. Higher 
detection limits of 0.1 picomole75 were obtained using a two step HPLC purification 
and 32P postlabelling system. Monoclonal antibodies have been raised to both 8A and 
cC. Significant levels of cross-reactivity to other etheno adducts and unmodified 
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nucleosides was reported. The antibodies were used to detect these adducts with 
sensitivities of 980 femtomoles and 800 femtomoles respectively using competitive 
ELISA76. More specific monoclonal antibodies to A and cC have been raised and 
were used in competitive RIA with a detection sensitivity of 187 femtomoles for both 
adducts77. These antibodies have also been used to detect etheno adducts in DNA 
hydrolysates from the liver, lung and brain of rats exposed to vinyl chloride. After 
HPLC purification the molar ratios detected were 0.6 x 10-7 to 1.3 x 10-7 for cA]dA 
and 1.95 x 10-7 to 4.92 x 10-7 for cC/dC78. The levels of all the vinyl chloride induced 
adducts were measured in DNA hydrolysates from the liver, lung and kidney of rats 
exposed to vinyl chloride. oeG was measured by on line fluorescence HPLC, sG by 
isotope dilution mass spectrometry using ['3C4] cG as an internal standard and EA and 
cC by HPLC followed by competitive RIA. The same spectrum of adducts was found 
in all three organs with oeG representing 98% of all adducts. Levels of cC and cG 
each accounted for 1% of the total adduct number of adducts while EA was present at 
lower concentrations79. Monoclonal antibodies to EC and EA have also been used in 
immunoaffinity chromatography to isolate and concentrate these adducts in the 
presence of other nucleotides. Used in conjunction with 32P post labelling the 
detection limits for this system were 50 attomoles of each etheno adduct 
80  or 4 etheno 
adducts per i09 parent deoxynucleotides75. This technique has also been used to 
analyse liver DNA from untreated rats with detection limits of 0.5 x 10-9 etheno 
adducts per parent deoxynucleotides81. This study found low but unspecified 
concentrations of both cA and EC in these tissues indicating endogenous production of 
these adducts. 
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AIMS OF THE PROJECT 
Quantitative determination of DNA adducts is essential for effective 
assessment of the risks associated with exposure to chemical carcinogens. DNA 
adducts are present at levels below one adduct in i07 nucleotides. Selective 
enrichment of adducts from the biological milieu is required to facilitate their 
detection at these low abundances. 
The primary aim of this project is to develop a system to enrich and quantify 
low levels of EC from the large excesses of nucleotides present in biological samples 
using immunochemical methods. 
The mutagenic properties of EC have been described. However, the molecular 
basis of this mutagenicity is not understood. The secondary aim of this project is to 
investigate the base-pairing properties of cC by thermodynamic and structural 
methods to rationalise the mutagenicity of cC. 
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RESULTS AND DISCUSSION 
Preparation of EC Conjugated Protein 
Nucleic acids are natural products common to all cells and as such have low 
immunogenic potential. To induce the immune system into producing an immune 
response to nucleic acids researchers have covalently and electrostatically bound 
them to carrier proteins82'83. Nucleosides also require protein conjugation as they 
escape detection by the immune system due to their small size. Numerous methods 
have been employed to bind nucleosides to carrier proteins. This involves the 
introduction of a reactive functionality onto the nucleoside which is capable of 
reacting with amino acid residues on the protein 84. 
Previous work to produce monoclonal antibodies to etheno adducts 
76,77  used 
the ribose sugar analogue of FC for protein conjugation (figure 19). The vicinal diol 
group was oxidised with periodate to open the sugar ring to form aldehyde groups. 
These react with lysine residues on the protein and the resulting aldimine system is 
stabilised by reduction with borohydride to form a morpholino ring system. 
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Figure 19: Protein Conjugation to a Nucleic Acid Riboside 
A different approach was used in our work. A spacer arm with a carboxy 
terminus was introduced onto the 3'-hydroxyl group of deoxyribose cC. The 
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carboxylic acid moiety was then the point of reaction for subsequent amide bond 
formation with lysine residues on the carrier protein. This method is advantageous as 
it preserves the deoxyribose ring and thus the immunogenic determinant is more 
closely related to the antigen. In addition, previous research into immunogenic carrier 
protein conjugates found that antibodies of greater antigenic specificity are produced 
when the antigen is located distally from the carrier protein by the introduction of a 
spacer arm 85 
The preparation of the cC conjugated protein involved a five step synthesis 
(figure 20). cC was synthesised by a procedure modified from that of Srivastava et 
a186. Bromoacetaldehyde buffered to pH 4.5 was added to a similarly buffered 
solution of dC as the reaction is kinetically favoured at this pH. Before 
functionalisation of the 3' hydroxyl group the 5' hydroxyl was selectively protected 
by addition of a 4,4'-O-dimethoxytrityl functionality by the method of Srivastava et 
a186. Succinic anhydride was used to introduce a five bond spacer arm with a carboxy 
terminus onto the 3' ribose sugar position. The labile dimethoxytrityl group was 
removed on addition of mild acid and due to the resulting high hydrophilicity the 
product was purified by reverse phase HPLC. Conjugation to the carrier protein was 
achieved via an activated ester of the carboxyl group formed by addition of a 
carbodiimide in the presence of the protein. Two protein conjugates were prepared 
from the proteins bovine serum albumin (BSA) and chicken gamma globulin (CyG). 
The proteins were examined for EC conjugation by analysis of the UV 
absorbances of free protein, protein conjugate and cC in the region of 240 to 300nm. 
Comparison of the profiles revealed significant "cC-like" absorbance in the protein 
conjugates (figure 21a and figure 21b). The cC conjugated BSA was characterised 
further by determining the number of cC residues per protein molecule using the 
method of Habeeb87. This technique labels free primary amino groups with 
trinitrobenzene suiphonic acid. Free lysine residues on the free protein and conjugate 
were labelled in this way and their numbers estimated spectrophotometrically by 
their absorbtion at 335nm. The free protein was calculated to bear 60 surface lysine 
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Figure 20: The Conjugation of EC to Proteins 
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LU 
Figure 21a: UV Scans of EC, BSA and EC Conjugated to BSA 
Figure 21b: UV Scans of cC, CyG and EC Conjugated to CyG 
The EC conjugated BSA was calculated to have 35 free lysines. The average ratio of 
EC to carrier protein was therefore approximately 25:1. 
The conjugates were sent to Shell Research Ltd. laboratories for the 
production of anti-EC monoclonal antibody secreting cell lines. The EC conjugated 
BSA was used in murine immunisations and the cC conjugated CyG was used to 
screen and select the resulting hybridoma cell lines and also in subsequent antibody 
characterisation. The methods and procedures used were similar to those outlined in 
Chapter 2. 
Initial Characterisation of the Antibody Secreting Cell Line 
Two mice were immunised at Shell. Preliminary experiments examined the 
most promising hybridoma cell line for reactivity to cC. The dot-blot method of 
analysis was used. 
Oligonucleotides bearing site specific cC residues (Oligos A and B) as well as 
an unmodified oligonucleotide (Oligo C) were synthesised by automated solid phase 
DNA synthesis using phosphoramidite chemistry (table 1). The cC nucleoside was 
Oligonucleotide Sequence 
Oligo A TCT TAG CAG cCTC ATG ATC TG 
Oligo B cCCT TAG CAG CTC ATG ATC TG 
Oligo C TCT TAG CAG CTC ATG ATC TG 
Table 1 
prepared by the method of Srivastava et a186 with the addition of dimethoxytrityl onto 
the 5' hydroxyl and a phosphoramidite group onto the 3' hydroxyl positions (figure 
22). 
It has been reported that the FA ring opens at the C2 position of the 
pyrimidine heterocycle when exposed to aqueous base 
87 (figure 23). This has 
consequences in automated DNA synthesis as the final deprotection and resin 
cleavage step uses concentrated ammonia at 60°C. In order to determine whether the 
structurally similar ring system in cC undergoes this reaction cC was subjected to 






Figure 22: The Synthesis of C Phosphoramidite 
(i)NaOH 
Figure 23: The Reaction of FA with Nucleophilic Base 
'H NMR and TLC revealed that FC was stable under these conditions. After DNA 
synthesis the oligonucleotides were purified by reverse phase HPLC. The base 
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composition was confirmed by digesting small quantities of the oligonucleotides to 
produce nucleosides using the enzymes snake venom phosphodiesterase II and 
alkaline phosphatase. The enzyme digests were analysed by reverse phase HPLC 







dC 	T/dG 	dA CC 
Figure 24: Enzyme digest 
The oligonucleotides were applied in known concentrations to nylon 
membranes and covalently fixed by UV irradiation. The membranes were soaked in 
undiluted hybridoma culture medium and antibodies binding to the membrane were 
detected by anti-mouse immunoglobulin HRP conjugate and DAB (figure 25). 
Antibodies binding to the membrane were visualised in the regions fixed with Oligos 
A and B down to a lower concentration of 500 attomoles. No binding to Oligo C was 
detected at an upper concentration of 50 picomoles. It was concluded that the 
difference in antibody binding shown between Oligos A and B was due to the 
increased steric hindrance encountered by the antibody binding site to a centrally 
positioned CC. No such steric hindrance is encountered at the 5' end of the 
oligonucleotide. 
The level of sensitivity exhibited by the antibody in this preliminary dot-blot 
examination indicated an antibody of high selectivity and affinity to CC and the 
characterisation of this hybridoma cell line was continued. 
40 
5 500 50 5 500 





- - 	-- _I c1 
Figure 25: Comparison 01 Imniunoreacuvity 01 uligo i-i. uiigu w1u 
Antibody Purification 
The cell line was cultured to produce large volumes of cell culture medium. 
This was partially purified and concentrated by salt fractionation, taking a 50% 
ammonium sulphate cut which precipitated the antibody along with other proteins. 
This was purified further by one of the following methods: 
anion exchange HPLC, 
strong cation exchange HPLC, 
Protein-A affinity chromatography. 
The purification efficiency of each method was compared in terms of protein yield 
but most critically in terms of purity and titre using the same sample of cell culture 
medium (table 2). The yield was determined spectrophotometrically assuming that an 
antibody solution of lmg.mF' absorbs 1.4 OD at 280nm. This "rule of thumb" was 
used throughout to calculate the concentration of antibody solutions. The purity of 
antibody solutions was determined by analytical SDS-PAGE. 
Method Yield jig protein/ml 
culture medium 
Purity Titre 
Anion Excange HPLC 23 unpure 1/3500 
Cation Exchange HPLC 26 unpure 1/3000 
Protein-A Affinity Chromatography 17 pure 1/9000 
Table 2 
Gels were run under reducing conditions with -mercaptoethano1 which cleaves 
disulphide bonds. This breaks interpeptide bonds within antibodies. The molecule 
was therefore visualised as two distinct bands. One band at approximately 49,000 
Daltons and the other at 25,000 Daltons corresponding to the heavy and light chains 
respectively (figure 26). Antibody titre was determined using ELISA by titrating 
dilutions from lmg.m11 of antibody using plates coated with EC conjugated to CyG. 
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Figure 27: Comparison of Antibody Purification Methods 
Protein-A affinity chromatography proved to be the best purification 
technique. Protein-A is a protein isolated from the cell wall of the bacterial strain, 
Staphiococcus aureus88. It selectively binds antibody molecules at the Fc region. 
This method provided pure antibody of high titre. The ion exchange HPLC methods 
provided large amounts of protein but this was of a heterogeneous nature and these 
antibody samples were also less active. 
Antibody samples were stored at 4°C or -20°C with no obvious deterioration 
in performance. Samples were also freeze dried but this proved counter productive as 
the protein was insoluble on attempted rehydration. 
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Antibody Characterisation 
Subsequent to obtaining large amounts of pure protein the antibody 
characterisation was continued to determine whether it would be suitable for an 
imnnmoaffinity chromatography application. The following criteria were used: 
antibody isotype, 
reactivity to cC, 
affinity to cC, 
cross-reactivity with normal nucleosides, 
cross-reactivity with other vinyl chloride induced DNA adducts. 
Antibody Isotype: The antibody isotype was established using an antibody 
isotyping kit with class and subclass specific anti-mouse immunoglobulin HRP 
conjugates in an ELISA. The antibody was found to be of the IgG isotype and 
subclass 2b. 
Reactivity to EC: EC and Oligos A and B were tested in competitive ELISA to 
determine their ability to inhibit antibody binding to plates coated with PC 
conjugated CyG. All three compounds inhibited antibody binding (figure 28) and 






Differences in antibody reactivity between the three compounds can be correlated 
with antigen availability to the antibody binding site. The antigen in Oligo A due to 
central positioning in the oligonucleotide is the most sterically inhibited followed by 
Oligo B and then cC. 
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Figure 28: Comparison of the Immunoreactivities of EC, Oligo A and Oligo B 
3) Affinity to C: To obtain a more accurate measure of antibody affinity, known 
quantities of labelled cC were titrated by ELISA on antibody coated plates in a 
Scatchard experiment89. Scatchard analysis utilises the equation: 
{Abb]/[Ab f] = Ka[AgJ - Ka[Abb] 
where: Abb is the concentration of antibody binding antigen, 
Ab f is the concentration of antibody not binding antigen, 
Ka  is the antibody affinity, 
Ag is the total concentration of antigen. 
Plotting [Abb]/[Ab f] against [Abb] gives a straight line of gradient Ka  and intercept 
Ag and so if [Abb] and [Ab f] are known Ka  can be experimentally determined. 
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Figure 29: UV Scans of EC, Alkaline Phosphatase and Alkaline Phosphatase 
Labelled EC 
Figure 30: Dot Blot of Immunoreactivity ot Alkaline i-'nospnatase Laoelleu 
The antibody was used in the solid phase to simulate the conditions 
encountered in immunoaffinity chromatography. cC was labelled with the enzyme, 
alkaline phosphatase. The labelling procedure was similar to that used to prepare the 
EC conjugated BSA. The reaction time was shortened to 10 minutes to ensure low 
conjugation levels and to preserve the enzyme activity. Successful conjugation was 
determined by examination of the respective UV scans of EC, alkaline phosphatase 
and the reaction product (figure 29). Dot-blots showing strong positive signals were 
also obtained when the alkaline phosphatase labelled with EC was fixed to 
nitrocellulose membrane and incubated with the antibody and anti-mouse 
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The alkaline phosphatase labelled EC was titrated on antibody coated plates 
(figure 31). The concentrations that gave the linear response in the curve were used 
in the Scatchard experiment. These concentrations were determined in terms of the 
protein rather than the antigen as it was assumed that the size of an alkaline 
phosphatase molecule (140,000 Daltons) would preclude multiple antigen binding to 
one antibody. The titration was repeated using these concentrations alongside 
standards of these concentrations. This gave readings for the concentration of antigen 
bound and the total concentration of antigen. The Scatchard calculation gave a plot 
indicating an antibody affinity of 1.8 x 108  M' in the solid phase (figure 32). 
Figure 32: Scatchard Plot 
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4) Cross-reactivity with Normal Nucleosides: The nucleosides: dA, dC, dG, T and 
U were tested as inhibitors to antibody binding in competitive ELISA (table 4). The 
Inhibitor Upper Concentration Used/mM % Inhibition 
dA 4.3 0 
dC 19.9 0 
dG 2.3 0 
T 14.7 13 
U 50.0 40 
Table 4 
antibody was found to be completely unreactive to dA, dC and dG upto the limits of 
compound solubility. T and U were found to exhibit some antibody binding at just 
below saturation concentrations. This slight cross-reactivity of the antibody between 
the compounds sC, T and U can be rationalised by examination of their structures 
(figure 33). All three bear similarities in size, shape and electrostatic charge 
distribution. All have pyrimidine heterocycles with trigonally coordinated nitrogens 
at the N' and N3 positions and a C5 to C6 double bond. The ring systems are also 
substituted at the C2 and C4 positions by double bonds to heteroatoms. 
(a) (c) 
Figure 33: The Structural and Electrostatic Similarities of a) cC, b) T and c) U 
5) Cross-reactivity with Other Vinyl Chloride Induced Adducts: The antibody 
was also examined for any class specific properties which would enable it to bind 
other vinyl chloride induced DNA adducts. The nucleosides, EA, cG2, and an 
analogue of oeG plus the imidazole ring opened form were synthesised. 
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cA was synthesised from dA by a method modified from the procedure of 
Srivastava et a186 using bromoacetaldehyde (figure 34) As with the synthesis of CC 
the reaction was buffered to pH 4.5. This is the pH where the reaction proceeds most 
quickly. However, it was imperative that the pH remain above 4.0 as the starting 









Figure 34: The Synthesis of EA 
cG2  was synthesised from G in three steps by a method modified from the 
procedure of Boryski90  (figure 35). Here guanosine was used as the starting material 
as the ribose sugar is less susceptible to depurination relative to the deoxyribose 
sugar91. To increase the solubility of guanosine in organic solvents it was selectively 
protected at the 3' and 5' ribose hydroxyls to give a cyclic silyl derivative. This was 
alkylated at the N' position with bromoacetaldehyde diethylacetal. Subsequent 
imidazole ring closure was achieved upon the addition of methanolic acid which also 
freed the 3' and 5' ribose hydroxyls. 
The synthesis of oeG required CEO which was commercially unavailable and 
required specialised equipment to prepare. Therefore a structurally similar analogue, 
2-amino-6-oxo-N7-ethoxy-3-3-D-ribofuranosy1 purine (alkG) was synthesised by the 
method of Roe et a!92 (figure 36). dG alkylated at the N7  postion is known to open 
the imidazole ring under physiological conditions 
93  (although an imidazole ring 

















Figure 35: The Synthesis of cG2 
(1)tetraisopropyldisiloxy chloride 
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Figure 36: The Synthesis of alkG 
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in vitro). The ring opened compound (roalkG) was synthesised by addition of 
nucleophilic base (figure 37). 
OH 
? NH _ 





NH HO OHCf 
[121 
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Figure 37: The Synthesis of roalkG 
The antibody was unreactive in competitive ELISA experiments to all of the 
compounds synthesised even at saturation levels (table 5). This was slightly 
surprising as LA and LG2 were predicted to show some reactivity due to close 
similarities to EC in structure and electrostatic charge distribution (figure 38). These 
compounds all bear the same imidazole ring and in cC and cG2 this is fused to a 
pyrimidine ring with an oxo substituent. The lack of cross-reactivity possibly 
indicates that the antibody binding site is too small to accommadate these bulkier 
DNA adducts although other properties of antibody binding such as dipole moments, 
hydrophobicity, polarity and H-bonding may account for this observation. 
Inhibitor Upper Concentration Used/mM % Inhibition 
FA 2 0 
cG2 2 0 
alkG 48 0 






Figure 38: The Structural and Electrostatic Similarities of cC, cA and cG2 
Summary 
The results indicate an antibody of high affinity to cC. This affinity is also 
maintained when the antibody is bound to a solid phase. This is crucial to the 
proposed utilisation of the antibody in an immuno affinity column. The antibody was 
also found to be extremely specific for EC although binding to T was also observed at 
very high concentrations of that nucleoside. This low level of cross-reactivity does 
have serious implications for the purification of EC in the presence of large excesses 
of nucleotides. The results indicate that inhibition of cC binding by T will occur at 
greater than 20 x 106  fold excesses of nucleosides (assuming equimolar quantities of 
all four nucleosides). When attempting to purify low levels of cC from human cells 
which contain 3 x 10 nucleotides, serious problems of T inhibiting EC binding could 
be encountered. However, this problem cannot be readily circumvented as cross-
reactivity between two similar compounds cannot be avoided. 
Immunoaffinity Column Construction 
The chemical methods used to covalently couple antibodies to a solid phase 
are dependent on the availability of sites on the antibody that can be alkylated. These 
electrophilic or nucleophilic centres can be protonated and their availability is 
therefore pH dependent. One property of a protein that indicates the propensity to 















Figure 59: Isoelectric rocusing 'ad 
The p1 of the antibody was determined by an isoelectric focusing gel to be in 
the range of pH 5.85 to 6.55 (figure 39). This indicates that within these pHs the 
antibody has zero overall electric charge but at higher pHs more acidic residues will 
become deprotonated and at lower pHs more basic residues will become protonated. 
Many common coupling chemistries use lysine residues as alkylation points and 
therefore solid phase antibody coupling using these methods is favoured at pHs 
above the p1. 
The antibody proved to be very sensitive to covalent solid phase coupling and 
a number of different coupling chemistries were tried before a successful 
immunoaffinity column was produced (table 7). 
Coupling Method Coupling Efticiency/% Column 
Immunoreactivity 
CNBr agarose 89 inactive 
Aldehyde agarose 72 inactive 
Protein-A HiTrap 13 inactive 
Protein-A agarose (method 1) 98 inactive 
Protein-A agarose (method 2) 94 inactive 
Hydrazide agarose 37 active 
Table 7 
Initially, cyanogen bromide activated agarose was used (figure 40). However, 
despite a high coupling efficiency the antibody was inactive and no antigen could be 





Figure 40: Antibody Coupling to Cyanogen Bromide Activated Agarose 
It was thought that the cyanogen bromide method was too harsh and antibody 
coupling was attempted using aldehyde activated agarose. This milder method uses 
aldehyde groups on the support to form Schiff's bases with lysine residues on the 
antibody which can then be stabilised by reduction with cyanoborohydride (figure 
41). 
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H0 (1) 	NAb H 	 HH kNHAb 
antibody 
sodium cyanoborohydride 
Figure 41: Antibody Coupling to Aldehyde Activayted Agarose 
Prior to using this coupling method the antibody was incubated in the presence of 
sodium cyanoborohydride and titrated by ELISA against untreated antibody to 
determine whether the reductant could be detrimental to antibody activity. The 
reductant was found to have no effect and the antibody remained active. Again a high 
coupling efficiency was achieved using this method but the column proved 
ineffective in binding the antigen. 
A strategy involving the binding of the antibody to Protein-A coupled agarose 
followed by chemical crosslinking to create a permanent antibody-Protein-A 
complex was attempted. It was thought that this could provide the antibody with 
additional stability in the solid phase. 
NH 	NH 
(i) 
F ProteiuA.NH2 	 ProteinAN4\'NHAb  
(i) antibody; dinthyIpimelimidate 
Figure 42: Antibody Coupling to Protein-A Agarose 
Initially, commercially available HiTrap columns (Pharmacia) were used. 
HiTraps contain Protein-A bound to agarose housed in compact columns which 
allow buffer and sample addition by syringe. Dimethyl pimelimidate was the 
crosslinking agent used to create the permanent antibody bound matrix (figure 42). 
After coupling, little antibody was found bound to the matrix. As the antibody is 
known to bind to Protein-A this was attributed to the high back pressures 
encountered when using the column and incomplete mixing of antibody and 





using unpacked Protein-A agarose in a gravity column. Successful antibody binding 
was obtained and very high coupling efficiencies were achieved. However, no 
antigen binding was observed. The crosslinking agent was examined for detrimental 
effects on antibody acivity. ELISA revealed that the activity was drastically reduced 
when the antibody was incubated with the crosslinker relative to unexposed antibody 
(figure 43). This experiment indicated that the antibody was extremely sensitive to 
-.-- 10mM Crosslinker 
-.- 20m1\4 Crosslinker 
A 	No Crosslinker 
0 	 2 	 4 	 6 	 8 
Number of Double Dilutions of the Reaction Mixture 
Figure 43: Comparison of Immunoreactivity Before and After Reaction with 
Crosslinker 
electrophilic reagents. All the previous coupling chemistries used also alkylated the 
antibody at nucleophilic centres. To verify this further the antibody was acetylated 
using carbodiimide and acetic acid buffered to pH 6 (figure 44) after which it was 
found by ELISA titration to be deactivated with respect to unacetylated antibody 
59 
J~ AbNH2 	)o AbNH CH3 
(i)CH3CO2H; ethyl (dinthyIaminopropy]) carbodiimide 
Figure 44: The Aceylation of the Antibody 
(figure 45). The coupling method was modified by "preactivating" the Protein-A 
agarose with crosslinker to reduce the exposure time to the antibody. This also 
successfully coupled the antibody but the matrix would not bind any antigen. 
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Figure 45: Comparison of the Immunoreactivities of Unacetylated and Acetylated 
Antibody 
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It was assumed that the antibody binding site was dependent on amino acid residues 
which are very susceptible to alkylation. 
An alternative, site directed approach to solid phase coupling was attempted. 
This utilised carbohydrate residues as points of alkylation. These are situated on the 
Fe region and are therefore remote from the antibody binding sites. The carbohydrate 
residues provided vicinal diol groups which were oxidised to aldehydes with 
periodate. These provided electrophilic points for reaction by a solid support 
activated with nucleophiles. This approach was therefore orthogonal to the methods 
used previously. Hydrazide activated agarose was used (figure 46) and although the 
coupling efficiency was reduced relative to some of the previous methods a column 
was produced capable of antigen binding. 
rNHNH2 	) rNHNAb 
(i) antibody 
Figure 46: Antibody Coupling to Hydrazide Activated Agarose 
Immunoaffinity Column Operation 
The optimal conditions to release the antigen bound to the column were 
determined by the following criteria: 
efficiency of antigen release, 
ease of eluting buffer removal, 
column reuse. 
ELISA was used to measure antibody binding in the presence of agents that disrupt 
the interactions between antibody and antigen. This revealed a number of possible 
eluting conditions (table 8). 
Of these conditions, organic solvents showed promise as they are easily 
removed by evaporation to give pure antigen. Evaporation of the other solvent 
systems would leave salt residues. Subsequent desalting would be impractical as gel 
filtration methods are only effective for high molecular weight antigens. 
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Type of Eluent Eluent % Binding 
Physiological PBS/T 100 
Organic solvent 40% methanol 55 
60% methanol 46 
80% methanol 33 
100% methanol 12 
40% ethanol 52 
60% ethanol 38 
80% ethanol 23 
100% ethanol 9 
Salts 1M sodium sulphate 94 
1M sodium chloride 55 
1M sodium iodide 45 
3M sodium sulphate 57 
3M sodium chloride 30 
3M sodium iodide 5 
pH 0.1M glycine.NaOH pH 11 5 
0.1M glycine.HCI pH 2 4 
Table 8 
To establish what irreversible effects these conditions might have on the 
protein the free antibody was exposed to these solutions which were then removed 
before titration by ELISA against unexposed antibody (figure 47). 
The free antibody was found to be irreversibly damaged and inactive after 
exposure to organic solvents which precludes their use as eluting buffers if the 
columns are to be reused. However, acid conditions at pH 3.0 were observed to be far 
less damaging to the antibody and if acetic acid was used the eluting solution could 
be removed in vacuo to give uncontaminated antigen. 
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Figure 47: Comparison of Immunoreactivities After Exposure to Elution Conditions 
ELISA was used to find the optimum pH that could release the antigen with 
the least damage to the antibody. It was found that pHs in the range 7.4 to 4.0 did not 
affect antibody binding of the antigen. Below pH 4.0 binding was reduced but at pH 
3.0 binding dramatically increased before sharply falling below pH 2.5 (figure 48). It 
is known that the Al4 postion of cC can become protonated at low pH (figure 49) but 
no PKa value has been reported 9496. A series of UV scans was recorded at a range of 
pHs and the absorbance was found to shift to higher wavelength at pH 3 (figure 50) 






Figure 48: ELISA at a Range of pHs 
Figure 49: Protonated cC 
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Figure 50: UV Scans of EC at a Range of pHs 
The ELISA experiment suggests that the antibody is more reactive to the 
protonated form of EC. However at pHs below 3 these stronger interactions are 
disrupted possibly due to the denaturing of the protein structure and the antibody can 
no longer bind to the antigen. The optimal pH for antigen elution is therefore 2.5. 
An Alternative to Immunoaffinity Column Chromatogaraphy 
An alternative method of immunoaffinity chromatography using filters 
instead of columns was attempted (figure 51). This made use of commercially 
available centrifuge vials fitted with specific molecular weight cut-off filters 
(Amicon). 
Figure 51: Immunoaffinity Purification Using Amicon Centrifuge Vials 
In theory, the antibody and antigen would be incubated together in the vial 
above the filter and the vial then spun to remove unbound material. The antibody and 
bound antigen would remain above the filter by virtue of the antibody size. The 
bound material could then eluted by respinning the vial in the presence of an 
appropriate elution buffer. 
Unfortunately, the experiment was unsuccessful. It is possible that the 
working centrifugal speeds required to successfully operate the vials generated forces 
that disrupted the binding between antibody and antigen. However this is speculative. 
This method of antigen purification was therefore discarded and immunoaffinity 
column chromatography with gravitational elution was the preferred method. 
Antigen Detection 
The method of antigen detection is dependent on the form of antigen. 
Initially, Oligos A and B were used in the immunoaffinity system as the sensitive 
dot-blot detection method could be employed. However, this proved problematic as 
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the highly charged oligonucleotides were prone to bind non-specifically to the 
column. To reduce such non-specific binding of charged molecules, high ionic 
strength buffers need to be used but these also disrupt the specific binding between 
antibody and antigen. 
cC nucleoside was also used. Nucleosides cannot be bound to nylon 
membranes so the dot-blot method of detection was precluded and competitive 
ELISA was used. This method could detect picomole levels of cC but was prone to 
inaccuracies due to aberrant readings. In addition, using ELISA to detect the antigen 
means the antibody is used in both the purification and detection steps of this 
application. This could prove to have detrimental effects. 
It has been demonstrated that the antibody cross-reacts with T and U and it 
may also cross-react with other molecules in a biological sample. Unknown 
quantities of these compounds could co-elute with cC and these contaminants could 
then be detected along with cC leading to inaccurate results. A preferred system is an 
orthogonal approach whereby the antibody is used to purify a sample but cC is 
detected by some physico-chemical means which would distinguish it from any 
contaminating compounds. 
Capillary Zone Electrophoresis (CZE) was the technique used to identify and 
quantify the constituents of a purified sample. This method separates compounds on 
the basis of charge, hydrophobicity and structure. These substances are then detected 
by their absorbance at a defined wavelength. The absorbance can be integrated to 
provide quantitative data. 
Only charged compounds can be run on CZE and therefore cC mono and 
bisphosphates were synthesised to test this system. It was thought that experimental 
levels of cC monophosphate running on CZE could be quantified by addition of cC 
bisphosphate. The bisphosphate spike being doubly charged would have a shorter 
retention time with respect to the monophosphate but, the UV absorbances would be 
very similar. CZE could be set at the UV maxima for these compounds (272nm) and 
the integrated quantity of monophosphate could be calculated from the known 
amount of bisphosphate. It was found that the charge difference between the mono 
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and bisphosphate made no difference to the quantities of these compounds picked up 
by the CZE. 
Immunoaffinity Chromatography with CZE 
Initially the column was used to capture samples of the synthesised PC 
monophosphate which were eluted from the column with 1 ml fractions of acetic acid, 
than analysed and quantified by CZE on addition of the CC bisphosphate spike. The 
column proved to be extremely efficient and quantitative capture of small amounts of 
CC was obtained in a number of experiments (figure 52 and table 9). 





To demonstrate column capture of CC in the presence of excesses of normal 
nucleotides, known quantities of herring sperm DNA were digested to 
mononucleotides with snake venom phosphodiesterase II. Complete digestion was 
verified by reverse phase HPLC. The immunoaffinity column was then used to purify 
10 picomole samples of CC monophosphate (ecp) contaminated with different 
quantities of DNA hydrolysate and spiked before analysis with CC bisphosphate 
(peep) (figure 53 and table 10). The immunoaffinity column could bind CC 
monophosphate even when mixed with 1000mg of DNA hydrolysate. 






However, at the higher levels of sample contamination the eluted samples from the 
immunoaffinity column suffered from considerable run-through from normal 








Figure 52: CZE Analysis of Elution Fractions from Immunoaffinity Column 
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Figure 53: CZE Analysis of Immunoenriched Samples of cC from Excesses of 
Normal Nucleotides 
EC monophosphate from the background nucleotides. As the quantities of the 
polluting nucleotides are approximately equal (given their differing UV absorbances 
at 272nm) this contamination is most likely due to non-specific binding to the solid 
phase matrix rather than cross-reaction of the normal nucleotides with the column 
antibodies. 
These experiments demonstrated the capability of the column to successfully 
retain quantities of cC even in the presence of large excesses of normal nucleotides at 
levels greater than 1 cC in 3 x lO nucleotides. 
The column was also used to analyse cC formation in synthetic single and 
double stranded DNA (ssDNA and dsDNA) exposed to the vinyl chloride metabolite, 
CAA in vitro. Single and double stranded DNA was exposed at two concentrations of 
CAA and the formation of cC monitored with time using the immunoaffinity 
chromatography followed by CZE system (figure 54, figure 55, figure 56 and table 
Time/minutes 0 1 5 10 15 30 60 
dsDNA at 60mM CAA 0 0 7.0 14.1 34.8 46.3 74.6 
dsDNA at 60jtM CAA 0 0 0 0 0 0.6 1.3 
ssDNA at 60mM CAA 0 18.3 40.6 76.0 109.9 139.3 164.7 
ssDNA at 60tM CAA 0 0 0.7 1.0 1.6 3.3 10.9 
Table 11 
As expected the production of adducts was greater and more rapid at the 
higher concentration of CAA. However, contrary to previous reports, adducts were 
found to form in both single and double stranded DNA34. The rate of adduct 
formation was significantly lower in double stranded DNA especially during the 
initial 10 minutes of CAA exposure. Thereafter the rates of adduct formation are 
similar. This is probably due to the disruption of the duplex structure by the 
destabilising effects of the etheno adducts (see later) making the interior structure of 
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Figure 55: Rate of Formation of 8C in Double Stranded and Single Stranded DNA at 
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Figure 56: Rate of Formation of EC in Double and Single Stranded DNA at 60i.iM 
Structural Studies 
In order to rationalise the base pairing properties of 8C within DNA structural 
studies were undertaken. Milligram quantities of oligonucleotides incorporating £C 
were synthesised by automated DNA synthesis using the cC phosphoramidite made 
as before (table 12). The oligonucleotides were rigorously purified using an 
orthogonal purification strategy. The oligonucleotides were initially purified by 









measured by CZE. The oligonucleotides were mixed together to form a number of 
duplexes (table 13). 
Sequence 
CGC ECTT TTT GCG 
CGC TTT TTcC GCG 
CGC cCAA AAA GCG 
CGC AAA AAC GCG 
CGC TTT TTT GCG 
CGC AAA AAA GCG 
Table 12 
Code Sequence 
NS d(CGC AAA AAA GCG / GCG TTT TTT CGC) 
EC.T d(CGC TTT TTT GCG / GCG FAA AAA CGC) 
cC.dA d(GCG AAA AAA GCG / GCG ECTT TTT CGC) 
T.EC d(CGC TTT TTT GCG / GCG AAA AAEC CGC) 
dA.0 d(CGC AAA AAA GCG / GCG TTT TTEC CGC) 
Table 13 
Sample mixtures were analysed by CZE to allow the addition of 
oligonucleotides in the correct proportions. Duplexes are retained by CZE longer 
than single strands and therefore CZE can be used to measure duplex purity and the 
ratios of the two strands. 
These DNA duplexes were used in: 
1) UV thermal denaturing studies, 
2)3 1P NMR studies, 
3) Crystallisation studies. 
1) UV thermal denaturing studies: The duplexes NS, EC.dA and 6C.T were 
examined for their stability when exposed to heat. Heat induces double strands to 
separate and this dissociation can be detected. Base stacking interactions in the 
double helix reduce the levels of UV radiation absorbed by the heterocyclic bases 
and when the duplex dissociates this hyperchromicity can be measured. When 
monitored as a function of temperature a melting curve is produced. The point of 
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inflection is known as the melting temperature (Tm) and corresponds to equimolar 
concentrations of single and double strands. Measurement of the Tin at a range of 
duplex concentrations allows calculation of the thermodynamic properties of free 
energy, enthalpy and entropy given the equations: 
1)1/Tm = (R/AH) in (CT/4) + AS/AH 
where: R is the gas constant (8.314 JK'moi'), 
AH is enthalpy, 
CT  is the concentration of single strands, 
AS is entropy. 
2) AG = AH - TAS 
where: AG is free energy, 
T is temperature. 
The thermodynamic parameters of hybridisation and the values for free 
energy (normalised to a temperature of 298K) for the three duplexes were calculated 











NS 53.3 -307.92 -0.83 -60.58 / 
cC.T 27.1 -217.69 -0.62 -32.32 1 	28.26 
EC.dA 25.2 -183.69 -0.50 -34.69 1 	 25.89 
Table 13 
Incorporation of 6C within double stranded DNA leads to considerable drop 
in the stability of this structure lowering the Tin by 26.2°C and 28.1°C and dropping 
the free energy (AAG298) by 25.89 and 28.26 for EC.dA and EC.T respectively. The 
small difference in stability between the cC.dA and the cC.T base pairs is consistent 
with the non-instructional nature of EC and also accounts for the slightly favoured 
EC.dA base pairing. The results mirror similar findings reported by Gibson et a!97 
(see publication). 
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Figure 57: Plot of the Thermodynamic Parameters of NS Duplex Hybridisation 












Figure 59: Plot of the Thermodynamic Parameters ofC.A Duplex Hybridisation 
2)31 P NMR studies: The duplexes NS, cC.dA and gC.T were also used in 31P NMR 
studies comparing the phosphorus resonances of the DNA backbone in these three 
duplexes. Bulky lesions often perturb the overall double helical structure leading to 
conformational changes in the DNA backbone. This distinction can be seen in the 
signals of the neighbouring phosphorus atoms as they will lie outside the normal 
range of chemical shifts. The 31P NMR spectra for all three duplexes show no 
significantly different resonances (figure 60) and so inclusion of cC opposite either a 
pyrimidine or a purine does not distort the overall duplex structure at NMR 
temperatures and DNA concentrations. 
3) Crystallisation Studies: All the duplexes synthesised were designed to be 
suitable for crystallisations to obtain X-ray diffraction data on duplex structure. Often 
DNA crystals are grown from palindromic sequences as these immediately hybrise 
due to their self-complementarity thus producing pure duplexes with no more than 
one single stranded molecule as an impurity. As well as purity, a stable structure is 
also required for successful crystal growth but as has been seen, inclusion of EC 
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Figure 60:'P NMR Snectra of NS. ECAA and EC.T 
drastically destabilises duplexes. This precludes inclusion of 8C in a palindromic 
sequence as it is unlikely that a stable duplex could form containing two such 
residues. Purity is paramount to crystal growth so all the duplexes were repurified by 
ion exchange FPLC under non-denaturing conditions. This separates any excess 
single strands from double stranded DNA. The native duplex sequence had 
previously been successfully crystallised and the X-ray crystal structure 
determined 98. The conditions reported in that study were used in initial crystallisation 
trials and these were subsequently varied. Microcrystals were obtained from all the 
duplexes but no crystals of sufficient size and quality could be obtained for X-ray 
diffraction. 
80 
CONCLUSIONS AND FUTURE WORK 
A highly selective and affinitive monoclonal antibody to cC was developed 
and successfully used in an immunoenrichment procedure. When used in tandem 
with a CZE detector this system could enrich picomole levels of cC from 1000mg 
excesses of DNA hydrolysate and quantify one cC from 108  normal nucleotides. 
The detection sensitivity of this system could be improved by employing 32P 
postlabelling followed by two-dimensional TLC post-immunoenrichment. This 
would allow femtomole or attomole levels of cC to be quantified. 
Kinetic studies using the immunoaffinity/CZE system examined the relative 
rates of formation of cC in double and single stranded DNA when exposed to CAA. 
It was found that the rate of formation of cC in single stranded DNA exceeded that in 
double stranded DNA. 
UV thermal denaturing and 31  P NMR studies on duplexes incorporating cC 
were carried to determine the base pairing properties of cC. It was found that cC has 
an extremely destabilising effect on the duplex although the overall structure is not 
greatly distorted relative to native DNA. 
Attempts to crystallise duplexes incorporating cC failed to produce crystals of 
the necessary size and quality for X-ray diffraction and total structure determination. 
Additional crystallisations using altered crystallisation conditions and different DNA 




All chemicals, buffer tablets, proteins and enzyme substrates were obtained from 
Aldrich, Sigma or Fluka. Silica gel 60 was obtained from Fluka. All cell culture 
media were obtained from Gibco with the exception of myoclone from ICN Flow. 
Cell culture plasticware was obtained from Costar. Microtitre plates were obtained 
from Nunc. Secondary antibody horseradish peroxidase (HRP) conjugated to rabbit 
anti-mouse immunoglobulins was obtained from Dakopatts. Antibody isotyping kit 
was obtained from Sera-lab. Hibond nylon and nitrocellulose membranes were 
obtained from Amersham. Bovine alkaline phosphatase was obtained from Bohringer 
Mannheim. Protein-A coupled to agarose, Protein-A affinity columns and 
Immunopure Ag/Ab Immobilisation kits 1 and 4 were obtained from Pierce. NAP5 
and NAP 10 columns were obtained from Pharmacia. 
Solvents 
All solvents were of analytical or HPLC grade. Anhydrous pyridine was distilled 
over CaR2. Anhydrous triethylamine (TEA) and diisopropylethylamine were stored 
over CaR2. Anhydrous acetonitrile was purchased from Applied Biosystems as DNA 
synthesis grade. Anhydrous tetrahydrofuran (THF) and diethyl ether (ether) were 
distilled over sodium and benzophenone. Pyrogen-free, reverse osmosis purified 
water was used throughout. 
Thin Layer Chromatography (TLC) 
TLC was carried out on 0.22mm layer silica gel 60 F254 on aluminium backed sheets 
obtained from Merck using the following solvent systems: 
ethyl acetate:methanol (5:1 v/v). 
ethyl acetate:acetonitrile (1:1 v/v). 
dichloromethane (DCM):methanol (9:1 v/v). 
ethyl acetate: methanol (1: 1 v/v). 
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Compounds were visualised by irradiation at 254nm. Sugar groups were visualised 
by anisaldehyde spray (para-methoxybenzaldehyde:acetic acid: conc.H2SO4:ethanol 
(5:1:1:100 v/v/v/v) with heating as dark blue to green colours. Dimethoxytrityl 
groups were visulalised by fuming HC1 as bright orange colours. 
Buffers, Cell Culyure Media and Substrates 
Acetate buffer: 200mM sodium acetate and 200mM acetic acid at pH 4.5. 
MES buffer: 100mM N -morpholinoethanesuiphonic acid at pH 6.2. 
HPLC buffers: details in appropriate experimental section. 
Enzyme digest buffer: 2M sodium chloride and 100mM Tris at pH 8.8. 
Phosphate buffered saline (PBS): tablets dissolved in water (200m1 per tablet) gave 
100mM phosphate and 50mM sodium chloride at pH 7.4. 
PBS/T: PBS with 0.05% w/v Tween-20. 
Blocking buffer: 10% w/v skimmed milk in PBS/T. 
DAB substrate: 3,3'-diaminobenzidine.4HC1 tablet and urea plus hydrogen peroxide 
tablet dissolved in water (15m1). 
PBS/BSA: PBS with 1% w/v Bovine Serum Albumin (BSA). 
pNPP substrate: para nitrophenyl-phosphate tablet dissolved in water (5m1). 
RPMI: RPMI 1640 with glutamax. 
RPMI/PS: RPMI with penicillin (200units.mr') and streptomycin (200 jig.mF'). 
10% complete media: RPMI/PS with 10% v/v myoclone, 2mM sodium pyruvate and 
amphotericin B deoxycholate (2.5.ig.ml'). 
5% complete media: as for 10% complete media but with 5% v/v myoclone. 
PBS/azide: PBS with 0.02% sodium azide. 
Binding buffer: 100mM Tris at pH 8.5. 
Eluting buffer: 100mM Glycine at pH 2.7. 
Neutralising buffer: 1M Tris at pH 9.0. 
SDS-PAGE solutions: details in appropriate experimental section. 
Coating buffer: 15mM sodium carbonate and 35mM sodium hydrogen carbonate at 
pH 9.5. 
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TMB substrate: 3,3' ,4,4' -tetramethylbenzidine liquid substrate system containing 
chromagen, buffer and hydrogen peroxide. 
Immunoaffinity column buffers: details in appropriate experimental section. 
CZE buffers: details in appropriate experimental section. 
UV melting buffer: 100mM sodium chloride, 10mM sodium hydrogen 
orthophosphate and 1mM sodium EDTA at pH 7.0. 
Crystallisation solutions: details in appropriate experimental section. 
FPLC buffers: details in appropriate experimental section. 
Instrumentation 
'H NMR spectra were recorded on a Bruker WP-200 (200.13 MHz) Fourier 
transform spectrometer. '3C NMR spectra were recorded on a Bruker WP-200 (50.32 
MHz) Fourier transform spectrometer. 31P NMR spectra were recorded on a Jeol 
FX90Q (90 MHz) Fourier transform spectrometer. UV spectra were recorded on a 
Perkin-Elmer Lambda 15 ultraviolet-visible specrophotometer. JR spectra were 
recorded on a Bio Rad FTS-7 Fourier transform spectrometer controlled by a Bio 
Rad SPC 3200 microcomputer. Positive ion fast atom bombardment (FAB) mass 
spectra were recorded on a Kratos MS 50 TC spectrometer using a 3-nitrobenzyl 
alcohol (3-NOBA) matrix. ELISA plates were read on a Molecular Devices Vmax 
kinetic microplate reader incorporating Softmax ELISA software package. 
Bromoacetaldehyde 111 92 
Br 
Bromoacetaldehyde diethyl acetal (86.4mmol, 20m1) and ethanol (lOml) were added 
to a solution of HCJ (1M, 60m1) and the resulting biphasic mixture vigorously stirred 
at room temperature. After 7 d the title compound was obtained as a monophasic 
solution. This was used unpurified. Dinitrophenyihydrazine derivative gave m/z 
(FAB) 302.97029 (M-1; Calc. for C8H7N404Br, 302.97289). 
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5,6-Dihydro-5-oxo-63-D-2 '-deoxyribofuranosylimidazo-[l ,2-c] -pyrimidine (EC) 
[21 86 
Compound [1] (43.2mmol, 6eq) was added in portions (9x5m1), to a stirred solution 
of 2'-deoxycytidine.HCl (1.9g, 7.2mmol, leq) in acetate buffer (40m1). The pH was 
periodically adjusted to 4.5 by the addition of sodium acetate solution (0.2M) and the 
solution warmed to 40°C. After 24 h the pH was adjusted to 8.5 with saturated 
NaHCO3 solution and concentrated in vacuo. The resulting paste was washed with 
methanol (80m1) and filtered. The filtered solid was washed with methanol (50m1) 
and the combined filtrates concentrated in vacuo. The product was purified by wet 
flash silica gel chromatography eluting with 0 to 5% gradient of methanol in DCM. 
The appropriate fractions were collected and concentrated in vacuo to yield the title 
compound as a pale yellow foam (1.577g, 6.28mmol, 87%), Rf (in A), 0.16; 
6H([H6]-DMSO) 7.80 (1 H, s, 2-H), 7.75-7.73 (1 H, d, 7-H), 7.39 (1H, s, 3-H), 6.73-
6.71 (11-1, d,8-H), 6.44-6.40 (11-1, t, 1'-H), 5.32-5.31 (1H, d, 3'OH), 5.10-5.07 (1H, t, 
5'OH), 4.31-4.28 (11-1, p, 3'-H), 3.87-3.84 (114, q, 4'-H), 3.63-3.59 (211, m, 5'-H) and 
2.22-2.18 (2H, m, 2'-H); 6([2H6]-DMSO)  146.51 (C), 133.12 (CH), 129.32 (2CH), 
113.88 (C), 99.26 (CH), 88.27 (CH), 86.27 (CH), 71.24 (CH), 62.02 (CH2) and 40.68 
(CH2); X.. (H20)/nm 293(shoulder), 280(shoulder) and 272; u(nujol mull)/cm' 
3459 (OH), 1659 and 1622 (C=O and aromatic ring system); m/z (FAB) 252.09841 





4-Dimethylaminopyridine (3 6mg, 280tmol, 0. leq) and compound [2] (750mg, 
2.98mmol, leq) were coevaporated with anhydrous pyridine (3 x lOmi) and 
dissolved in anhydrous pyridine (15m1) and anhydrous TEA (622j11, 451mg, 
4.47mmol, 1.5eq). 4,4'-Dimethoxytrityl chloride (1.31g, 3.87mmol, 1.3eq, 
recrystallised from 1% acetyl chloride in hexane) was added in four portions with 
stirred, in the dark, under an argon atmosphere at room temperature. After 24 h the 
reaction was quenched with the addition of water (20m1), concentrated in vacuo and 
coevaporated with toluene (3 x 20m1). The resulting brown gum was dissolved in 
DCM (50m1) and washed with saturated KC1 solution (50m1). The aqueous phase 
was washed with DCM (3 x 1 OOml) and the combined organic fractions dried over 
Na2SO4, filtered and concentrated in vacuo. The product was purified by wet flash 
silica gel chromatography eluting with a 0 to 4% gradient of methanol in 1% TEA in 
DCM. The appropriate fractions were concentated in vacuo to yield the title 
compound as a pale yellow foam (1.26g, 2.28mmol, 76%), Rf (in A) 0.79; H([2H6]-
DMSO) 7.79 (1H, d, 2-11), 7.52-7.50 (114, d, 7-H), 7.39-6.86 (14H, m, trityl-H and 3-
H), 6.45-6.43 (111, d, 8-H), 6.39 (11-1, t, 1'-H), 5.46 (11-1, d, 3'OH), 3.96-3.95 (1H, q, 
4'-H), 3.72 (61-1, s, Me), 3.54-3.38 (2H, m, 5'-H) and 2.52-2.48 (21-1, in, 2'-H); 
c([2H6]DMS0) 158.38 (C), 145.64 (C), 144.96 (C), 135.71 (C), 135.47 (C), 132.88 
(CH), 130.06 (CH), 128.21 (CH), 127.98 (CH), 113.51 (CH), 113.17 (C), 98.54 
(CH), 86.10 (CH), 85.94 (CH), 85.66 (CH), 70.16 (CH), 63.58 (CH2) and 55.31 
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(CH3); Xma max x(50°% ethanol)/nm 294(shoulder), 281, 273 and 234; D(flUjOl mull)/cm 





4-Dimethylaminopyridine (4.6mg, 46tmol, 0. leq) and compound [3] (250mg, 
460tmo!, leq) were coevaporated with anhydrous pyridine (3 x 5m!) and dissolved 
in anhydrous pyridine (5m1). Succinic anhydride (60mg, 598tmol, 1 .3eq) was added 
to the stirred solution under an argon atmosphere, in the dark at room temperature. 
After 72 h the solution was concentrated in vacuo and coevaporated with toluene (3 x 
5m1). The resulting brown gum was dissolved in DCM (50m!) and washed with 
water (lOmi). The organic phase was dried over Na2SO4, filtered and concentrated in 
vacuo. The product was purified by wet flash silica gel chromatography eluting with 
a 0 to 9% gradient of methanol in 1% TEA in DCM. The appropriate fractions were 
concentrated in vacuo to yield the title compound as a pale yellow foam (210mg, 
3221imol, 70%), Rf (in A) 0.425; 6H({2H6]-DMSO) 9.9-9.6 (1H, s, CO2H), 7.65 (11-1, 
s, 2-H), 7.58-7.56 (1H, d, 7-H), 7.37-6.78 (14H, m, trityl and 3-H), 6.59-6.55 (111, t, 
1'-H), 6.27-6.25 (1H, d, 8-H), 5.48-5.46 (1H, d, 3'-H), 4.20-4.19 (111, d, 4'-H), 3.72 
(611, s, Me), 3.52-3.41 (21-1, q, 5'-H), 3.02-2.98 (41-1, m, 7'-H and 6'-H) and 2.46-2.42 
(21-1, m, 2'-H); c([2H6]-DMSO)  176.16 (C), 172.50 (C), 158.38 (C), 145.48 (C), 
144.61 (C), 143.99 (C), 135.01 (C), 134.84 (C), 132.14 (CH), 129.81 (CH), 127.85 
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(CH), 127.71 (CH), 127.10 (CH), 126.83 (CH), 112.99 (CH), 112.55 (CH), 98.93 
(CH), 86.86 (C), 85.24 (CH), 84.05 (CH), 74.42 (CH), 54.94 (CH3), 44.75 (CH2), 
38.30 (CH2), 30.24 (CH2) and 29.79 (CH2); Am (50% ethanol)/nm 294(hump), 
281(shoulder), 272, 265(shoulder), 257(shoulder) and 232; U(flUjOl mull)/cm' 
3200-2500 (CO2H) and 1702 (C=O and aromatic ring system); m/z (FAB) 654.24518 
(M+1; Caic. for C36H36N309, 654.245 13). 
11,2-cl- 
pyrimidine [5] 
Compound [4] (50mg,77tmo1) was dissolved in acetonitrile (500ji1) and HC1 
solution (500j.il, 1M) added. After stirred at room temperature for 24 h the product 
was purified by reverse phase HPLC as described below eluting with: buffer A-water 
and buffer B-20% acetonitrile and using the following gradient: 
Time/min Flow Rate/ml.min' % Buffer B 
0 3 0 
3 3 0 
4 3 15 
25 3 70 
26 3 100 
28 3 100 
29 3 0 
32 0 0 
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The appropriate peak was collected, concentated in vacuo and freeze dried to yield 
the title compound as a white solid (14mg, 40mol, 52%), Rf (in A) 0.06; ? m (50% 
ethanol)/nm 293(shoulder), 281(shoulder), 272, 264(shoulder) and 257(shoulder); 
m/z (FAB) 352.11488 (M+l; Caic. for C15H17N307, 352.11489). 
Preparation of Ethenodeoxycytidine (EC) Immunogen 
BSA 	(Sigma) (6mg) and 1 -ethyl-3-(3-dimethylaminopropyl)carbodiimide.HC1 
(13mg, 84p.mol, 3eq) were added to MES buffer (2m1) and warmed to 32°C. A 
solution of [5] (10mg, 28pmo1, leq) in DMSO (2m1) also warmed to 32°C was added 
dropwise and a slight precipitate formed. The suspension was incubated at 32°C and 
after 24 h the product was purified by gel filtration NAP- 10 column chromatography 
to the manufacturer's specifications eluting with 50% ethanol. The conjugate was 
stored in 50% ethanol at -20°C until used. 
Preparation of EC Screen 
As for the sC immunogen replacing BSA with CyG. 
Characterisation of EC Immunogen 
EC immunogen (imi of 500jgml' in 50% ethanol) was warmed to 40°C. 4% 
NaHCO3 (imi) and 0.1% 2,4,6-trinitrobenzenesulphonic acid (imi) were added and 
the mixture incubated at 40°C. After 2 h 10% sodium dodecyl sulphate (imi) and 
HC1 (500jil, 1M) were added. BSA (im! of 500tgmr1 in 50% ethanol) was treated 
identically and the absorbance of both solutions read at 335nm against a blank of 
50% ethanol treated as above. 




3-Hydropropionitrile (3.4m1, 3.55g, 50mmol, 0.14eq) dissolved in anhydrous 
acetonitrile (20m1) was added dropwise, via a double ended needle under argon 
pressure, to a stirred solution of phosphorus trichioride (30.6m1, 350mmol, leq) in 
anhydrous acetonitrile (20m1), at room temperature. After 15min the solution was 
concentrated in vacuo and the resulting cloudy oil purified by Kugelrohr distillation 
(60°C, 0.4mmHg) to yield 2-cyanoethylphosphodichloride. NN-diisopropylamine 
(10.5m1, 74.9mmol, 0.21eq) dissolved in anhydrous ether (40m1) was added 
dropwise, via a double ended needle under argon pressure, to a stirred solution of the 
2-cyanoethylphosphdich!oride in anhydrous ether (40ml) at room temperature. After 
5min a white precipitate formed and the reaction mixture was filtered twice and 
concentrated in vacuo. The resulting yellow oil was purified by Kugelrohr distillation 
(140°C, 0.3mm Hg) to yield the title compound as a clear, colourless oil (5.2g, 16%), 
6([2H1]-CDC13) 180.25 (1P, s, P"). 
5,6-Dihydro-5-oxo-6 -D-5 '-O-dimethoxytrityl-2 '-deoxyribofuransylimidazo-






Compound [3] (392mg, 709mmol, leq) was coevaporated with anhydrous pyridine 
(3 x Sml) then with anhydrous THF (5m!) and dissolved in anhydrous THF (5m1) and 
anhydrous diisopropylethylamine (400i1, 2,3mmol, 3.2eq). Compound [6] (210pJ, 
222mg, 9401.lmol, 1 .3eq) was added dropwise with stirred, in the dark, under an 
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argon atmosphere at room temperature. After 10min solid 
diisopropylethylammonium chloride precipitated and the suspension stirred for a 
further 2 h. The reaction was quenched with the addition of anhydrous ethyl acetate 
(50m1) and the organic phase washed quickly with saturated KC1 solution (lOmi). 
The organic phase was dried over Na2SO4, filtered and concentrated in vacuo. The 
resulting yellow oil was purified by wet flash silica gel chromatography (pre-washing 
the silica gel with 1% triethylamine in anhydrous ethyl acetate) eluting with 
anhydrous ethyl acetate. The appropriate fractions were collected and concentrated in 
vacuo to yield the title compound as a white foam (33 5mg, 445 jtmol, 63%), Rf (in 
B), 0.70; 6([2H1 ]-CDC13) 149.42 and 149.02 (IP, d, P"5;  m/z (FAB) 754.33698 
(M+1, Calc. for C41H49N507P, 754.33694). 
Oligonucleotide Synthesis 
Oligonucleotide synthesis was performed using solid phase cyanoethyl-N,N-
diisopropylphosphoramidite chemistry on an Applied Biosystems 394 automated 
DNA sythesiser equipped with on-line long wave detector (498nm). All DNA 
synthesis reagents and phosphoramidite monomers were supplied by Applied 
Biosystems. Compound [7] was dried in vacuo with P205 for 24 h and used as a 
0.12M solution in anhydrous acetonitrile. In general all coupling efficiencies were 
>98.5%. "Trityl-off' sythesis was carried out and oligonucleotides were cleaved from 
the resin with concentrated ammonia and deprotected by incubation at 55°C in 
concentrated ammonia for 6 h. 
HPLC Analysis and Purification of Oligonucleotides 
Oligonucleotide analysis and purification was carried out by HPLC on a Gilson 
Model 306 equipped with a Brownlee Aquapore Octyl reverse phase column (10mm 
x 250mm).The eluting buffers used were: buffer A-lOOmM NH40Ac and buffer B-
100mM NH40Ac plus 25% acetonitrile eluting with the following gradient: 
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Time/min Flow Rate/ml.min' % Buffer B 
0 3 0 
3 3 0 
5 3 20 
24 3 70 
26 3 100 
28 3 100 
29 3 0 
32 0 0 
Analytical scale runs were performed at 260nm and 0.5aufs. Preparative scale runs 
were performed at 298nm and laufs. 
Enzymatic Digestion of Oligonucleotides 
Oligonucleotides (3 to 6 0D260 units) dissolved in enzyme digest buffer (500tl) were 
incubated at 37°C with snake venom phosphodiesterase I (0.05 units) and calf 
thymus alkaline phosphatase (0.75 units). After 48 h the solutions were analysed by 
HPLC as above using the following buffers: buffer A-0.1M NH40Ac and buffer B-
0. 1M NH40Ac plus 20% acetonitrile. 
Oligonucleotide Storage 
Oligonucleotides were desalted by gel filtration NAP-10 column chromatography to 
the manufacturer's specifications eluting with distilled water and stored at -20°C in 
frozen solutions or freeze dried solids. 
Dot Blot Protocol 
Oligonucleotide solution (500n1) was spotted onto nylon membrane and allowed 
to dry. 
The membrane was irradiated at 254nm for 5mm 
Blocking buffer (20m1) was applied and incubated at room temperature for 30mm 
The membrane was washed with PBS/T (5x). 
Anti-EC antibody (20m1 diluted to 1/1000 with PBS/T from approximately lmgmr 
stock solution) was applied and incubated at room temperature for 3 h. 
Repeated 4). 
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Rabbit anti-mouse antibody/HRP (20m1 diluted 1/1000 with PBS/T) was applied 
and incubated at room temperature for 1 h. 
Repeated 4). 
DAB substrate (lOmi) was applied and incubated at room temperature for 30mm 
This dot blot protocol was modified for protein fixation by using nitrocellulose 
membrane. This only required drying, irradiation being unnecessary. 
3 J3-D-2 '-deoxyribofuranosyl imidazo- [2,1-i] -purine (6A) [8] 
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Compound [1] (8.7mmol, 6eq) was added in portions (9 x lml) to a stirred solution 
of 2'-deoxyadenosine.H20 (400mg, 1.45rnmol, leq) in acetate buffer (20m1). The pH 
was periodically adjusted to 4.5 by the addition of sodium acetate solution (0.2M) 
and the solution warmed to 40°C. After 24 h the solution was concentrated in vacuo 
and triturated with 50% ether in ethyl acetate (lOOml). The resulting solid was 
filtered and washed with 50% ether in ethyl acetate and dried in vacuo to yield the 
title compound as a white solid (361mg, 1.33mmol, 91%), Rf (in A) 0.35; 6H([2H61-
DMSO) 9.28 (1H, s, 5-H), 8.54 (1H, s, 2-H), 8.07-8.06 (1H, d, 7-H), 7.56-7.55 (1H, 
d, 8-H), 6.50-6.45 (1H, t, 1'-H), 5.43-5.41 (1H, d, 3'OH), 5.05-5.00 (1H, t, 5'OH), 
4.47-4.44 (1H, p, 3'-H), 3.93-3.88 (1H, q, 4'-H), 3.68-3.50 (2H, m, 5'-H), 2.80-2.69 
(1H, m, 2'-H) and 2.43-2.34 (1H, m, 2'-H); c([2H6]-DMSO) 140.62 (C), 139.77 
(CH), 138.21 (C), 137.09 (CH), 132.83 (CH), 123.15 (C), 112.30 (CH), 88.99 (CH), 
83.99 (CH), 70.74 (CH), 61.70 (CH2) and under DMSO (CH2); ? m (H20)Inm 296, 
275, 266, 259; Um (flUjO1 mull)/cm' 3284 (OH) and 1642 (aromatic ring system); 
m/z (FAB) 276.10966 (M+1; Caic. for C12H13N503, 276.10961). 
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Guanosine (1.108g, 3.92mmol, leq) and 4-dimethylaminopyridine (49mg, 0.4mmol, 
O.leq) were coevaporated with anhydrous pyridine (3 x 25m1) and dissolved in 
anhydrous pyridine (75m1). 1 ,3-dichloro- 1,1 ,3,3-tetraisopropyldisiloxane (1 .526m1, 
1.36g, 4.31 2mmol, 1.1 eq) was added, dropwise, with stirred at room temperature. 
After 72 h the suspension was concentrated in vacuo and coevaporated with toluene 
(3 x 30m1). The resulting oil was dissolved in DCM (50m1), washed with saturated 
KC1 solution (30m1) and the aqueous phase extracted with DCM (3 x 50m1). The 
combined organic fractions were dried over Na2SO4, filtered, concentrated in vacuo 
and purified by wet flash silica gel chromatography eluting with 0 to 5% gradient of 
methanol in DCM. The appropriate fractions were collected and concentrated in 
vacuo to yield the title compound as a white solid (1.605, 3.06mmol, 78%), Rf (in C) 
0.26; 6H([ H6]-DMSO) 7.76 (11-1, s, 8-H), 7.34 (21-1, s, NH2), 6.53 (1H, s, OH), 5.69-
5.68 (11-1, d, 1'-H), 4.37-4.11 (1H, in, 2'-H), 4.05-3.88 (211, in, 4'-H and 3'-14), 3.48 
(611, s, 5'-H and propyl-H) and 1.03-0.97 (24H, ds, Me); c([2H6]-DMSO)  157.05 
(C), 154.06 (C), 150.78 (C), 128.50 (CH), 116.94 (C), 88.11 (CH), 81.18 (CH), 74.18 
(CH), 69.75 (CH), 60.83 (CH), 17.51 (CH3), 17.35 (CH3), 17.11 (CH3), 17.04 (CH3), 
13.00 (CH), 12.66 (CH), 12.55 (CH) and 12.22 (CH); Xm (H2O)/nm 282, 259, 
232(hump) and 213; U(flUjO1 mull)/cm' 3336, 3188 (OH, NH), 1699, 1625, 1578 
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To a solution of compound [9] (800mg, 1.52nimol, leq) in DMF (50m1), 
bromoacetaldehyde diethylacetal (356 j.il, 450mg, 2.28mmol, 1 .5eq) and powdered 
potassium carbonate (3 14mg, 2.28mmol, 1.5eq) were added. The suspension was 
stirred at 90°C and after 24 h the solution was concentrated in vacuo. The resulting 
oil was dissolved in DCM (50m1) and washed with saturated KCI solution (30m1). 
The aqueous phase was extracted with DCM (3 x 50m1) and the combined organic 
fractions were dried over Na2SO4, filtered and concentrated in vacuo. The product 
was purified by wet flash silica gel chromatography eluting with 0 to 2% gradient of 
methanol in DCM and the appropriate fractions were concentrated in vacuo to yield 
the title compound as a pale yellow foam (809mg, 1 .26mmol, 55%), Rf (in C) 0.77; 
6H([H6]-DMSO) 7.78 (1H, s, 8-H), 7.33 (2H, s, NH2), 6.88 (1H, s, OH), 5.70-5.68 
(1H, d, 1'-H), 4.73-4.68 (1H, t, 11-H), 4.38-4.27 (1H, m, 2'-H), 4.11-3.88 (2H, m, 4'-
Hand 3'-11), 3.70-3.53 (2H, m, 5'-H), 3.48 (4H, s, propyl-H) and 0.90-1.33 (36H, m, 
10-H, ethoxy-H and Me); 8c([2H6]-DMSO) 156.84 (C), 154.90 (C), 148.89 (C), 
128.47 (CH), 116.24 (C), 100.51 (CH), 87.84 (CH), 81.25 (CH), 74.13 (CH), 69.84 
(CH), 63.21 (CH2), 63.13 (CH2), 60.90 (CH2), 44.79 (CH2), 17.48 (CH3), 17.34 
(CH3), 17.08 (CH3), 17.01 (CH3), 15.36 (CH3), 13.00 (CH), 12.67 (CH), 12.55 (CH) 
and 12.22 (CH); A m (H20)/nm 275(hump) and 258; m (flUjOl mull)/cm' 3398, 
3195 (OH and NH), 1681, 1648, 1609,1570 and 1539 (C=O and aromatic ring 
system); m/z (FAB) 642.33501 (M+1; Caic. for C28H51N508Si2, 642.33545). 
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8,9-Dihydro-9-oxo-3-3-D-furanosy1imidazo- [2,1 -aJ -purine (6G2) 1111 
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Compound [10] (500mg, 780jtmol) was dissolved in methanol (lOml) and HCl 
solution (50m1, 1M) added. The solution was stirred at room temperature and after 24 
h the pH was adjusted to 7 with NaOH solution (2M). The solution was concentrated 
in vacuo and the resulting yellow oil purified by wet flash silica gel chromatography 
eluting with 0 to 9% gradient of methanol in 1% triethylamine in DCM. The 
appropriate fractions were concentrated in vacuo to yield the title compound as a pale 
yellow solid (158mg, 515i.imol, 66%), Rf (in C) 0.17; 84[2H6]-DMSO)  8.17 (1H, s, 
2-H), 7.62-7.61 (1H, d, 7-H), 7.45-7.44 (1H, d, 8-H), 5.83-5.81 (1H, d, 1'-H), 4.49-
4.45 (1H, t, 2'-H), 4.15-4.11 (1H, t, 3'-H), 3.94-3.89 (1H, q, 4'-H) and 3.68-3.51 
(2H, m, 5'-H); 8c([2H6]-DMSO)  151.48 (C), 150.50 (C), 145.93 (C), 137.41 (CH), 
116.77 (CH), 115.50 (C), 107.04 (CH), 86.94 (CH), 85.35 (CH), 73.87 (CH), 70.44 
(CH) and 65.09 (CH2); 2 m (H20)/nm 285 and 226; u(nujol mull) 3390 (OH), 
1709, 1594, 1578 and 1531 (C=O and aromatic ring system); m/z (FAB) 308.10084 
(M+1; Calc. for C12H14N505, 308.09949). 
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OO Nj NH2 
HO OH 
Ethylene oxide was bubbled into a stirred suspension of guanosine (2.83g, lOmmol) 
in glacial acetic acid (1 OOml) at room temperature until the turbid mixture cleared. 
After stirred for a further 20 min the reaction mixture was added to acetone (200m1) 
and ether (800m1) was added to precipiate the product. The solid was filtered, washed 
with ether (200m1) and dried in vacuo to yield the title compound as a white solid 
(3.195g. 8.26mmol, 83%), Rf (ifl A) 0.00; H([ H6]-DMSO) 9.32 (11-1, s, 8-H), 7.80-
7.50 (211, s, NH2), 6.50-6.10 (411, s, OH), 5.85-5.84 (111, d, 1'-H), 4.42-4.38 (3H, t, 
11-H and 2'-H), 4.18-4.14 (11-1, t, 3'-H), 4.00-3.98 (11-1, d, 4'-H), 3.78-3.57 (41-1, m, 
10-H and 5'-H) and 1.79 (3H, s, acetate-H); c([2H6]-DMSO) 153.88 (C), 153.02 
(C), 147.62 (C), 105.54 (C), 88.01 (CH), 83.24 (CH), 72.21 (CH), 67.06 (CH), 58.15 
(CH2), 56.96 (CH2), 49.68 (CH2) and 20.84 (CH3); Xmax(H2O)/flm 280, 256, 210; 
Umax(tlUJO1 mull)/cm-1 3333, 3479 (OH and NH), 1711, 1672, 1625, 1562 and 1523 
(C=O and aromatic ring system); m/z (FAB) 328.12563 (M+1; Calc. for 
C12H18N506, 328.12571). 
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HO N -,' 	PO NH2 
HO OH 
Compound [12] (ig, 258mmo1) was dissolved in H20 (lOmi) and conc. NH40H 
(40m1) added. The solution was stirred at room temperature and after 24 h was 
concentrated in vacuo and then freeze dried to yield the title compound as a white 
solid (854mg, 2.48mmol, 96%), Rf (in D) 0.32; Xm (H20)/nm 274; U(flUjOl 
mull)/cm 1 3328, 3156 (OH and NH), 1660 and 1578 (C=O and aromatic ring 
system); m/z (FAB) 346.13605 (M+1; CaIc. for C121119N507, 346.13627). 
Preparation of Alkaline Phosphatase Labelled EC (C/AP) 
A solution of compound [5] (1mg, 2.85mol, leq) in MES buffer (500j.tl) was 
warmed to 25°C and 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide.HC1 (1mg, 
2.85tmol, leq) was added. After 10min calf intestine alkaline phosphatase (50.il, 
500 jig in 3M NaCl, 1mM MgC12, lOOjiM ZnC12 and 30mM triethanolamine) was 
added with MES buffer (450[d) and incubated at 25°C for 5 h.The conjugate was 
purified by NAP-10 gel filtration chromatography to the manufacturer's 
specifications, eluting with PBS/BSA. A portion (lOOjil) was freeze dried and 
weighed against freeze dried PBS/BSA (lOOjil) to determine the quantity of 
conjugate. The conjugate was stored in PBS/BSA at 4°C until used. 
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Thawing Frozen Cell Lines 
Cryotubes containing the anti-SC monoclonal antibody cell line were removed from 
liquid nitrogen storeage and rapidly thawed with warm water. The contents were 
transfered, within a laminar flowhood to a sterile container and diluted with 
RPMI/PS (lOmi). The suspension was spun (500G, 5mm) and the supernatant 
discarded. The pellet was resuspended in warm RPMIIPS (lOmi) and kept at 37°C for 
30min The suspension was spun (500G, 5mm) and the supernatant discarded. The 
pellet was resuspended in 10% complete media (2m1), divided into two, 2m1 wells 
and stored in a CO2 incubator at 37'C. 
Maintaining and Expanding Cell Culture 
All cell manipulations were performed within a laminar flowhood. 5% complete 
medium was exchanged 3 times weekly. The culture was examined for cell growth 
and for growth exceeding 70% confluency the cells were suspended and transfered to 
a larger, sterile flask. This process was concluded when the culture was maintained in 
six, 1000ml flasks. The old medium was removed and spun (500G, 5mm) and the 
supernatant retained and stored at 4°C or frozen at -4°C. Fresh 5% complete medium, 
warmed to 37T, was added in equal volume and the cell culture returned to the CO2 
incubator at 37°C. Every month the cultures were transfered to fresh, sterile flasks to 
prevent microbial growth. 
Methods of Antibody Purification 
A) Ammonium Sulphate Precipitation 
Antibody was concentrated from hybridoma culture media by (NH4)2SO4 
precipitation. Saturated (NH4)2SO4, cooled to 4°C, was slowly added to an equal 
volume of hybridoma culture medium whilst stirred on ice, to give a 50% saturated 
(NH4)2SO4 solution. After 1 h the suspension was spun (8000G, 30mm) and the 
supernatant discarded. The pellet was dissolved in the minimum quantity of H2O and 
dialysed against PBS/azide (3 x 3000ml). 
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B) Ion Exchange HPLC 
Antibody purification was carried out by HPLC on a Gilson Model 306 equipped 
with 3 pumps and a fraction collector. 
Method 1: The HPLC apparatus was equipped with an Anachem Hydropore-AX 
Dynamax II ion exchange column (4.6mm x 100mm). The eluting buffers used were: 
buffer A-lOmM K2HPO4 at pH 7.4, buffer B-lOmM K2HPO4 at pH 7.4 plus 500mM 
NaCl. The sample buffer was: buffer C-Post (NH4)2SO4 concentrated antibody pre-
filtered through 0.45um and 0.2um filters. The following elution gradient was used: 
Time/mins Flow Rate/mimin' % Buffer B % Buffer C 
0 1.5 0 0 
1 1.5 0 0 
3 1.5 0 100 
13 1.5 0 100 
14 2.0 0 0 
18 2.0 0 0 
19 2.0 0 0 
21 2.0 0 0 
22 2.0 0.5 0 
23 2.0 25 0 
25 2.0 60 0 
28 2.0 60 0 
30 2.0 0 0 
34 2.0 0 0 
35 0.0 0 0 
Chromatography was performed at 280nm and laufs. The fraction collector started 
after 10 min and collected 2m1 fractions, the antibody eluting in fractions 13 to 19. 
Method 2: The HPLC apparatus was equipped with an Anachem Hydropore-SCX 
Dynamax II ion exchange column (4.6mm x 100mm). The eluting buffers used were: 
buffer A-20mM MES at pH 6.3 and buffer 13-20mM MES plus 500mM NaCl at pH 
6.3. The sample buffer was: buffer C-Post (NH4)2SO4 concentrated antibody pre-
filtered through 0.45p.m and 0.2tm filters. The following elution gradient was used: 
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Time/min Flow Rate/ml.min 1 %Buffer B %Buffer C 
0 2 0 0 
1 2 0 0 
2 2 0 100 
11 2 0 100 
12 2 0 0 
17 2 0 0 
18 2 70 0 
23 2 70 0 
24 2 70 0 
25 2 70 0 
26 2 0 0 
30 0 0 0 
Chromatography was performed at 280nm and 1 aufs. The fraction collector started at 
12 min and collected 2m1 fractions, the antibody eluting in fractions 7 to 11. 
C) Protein-A Affinity Chromatography Protocol 
The affinity column was equilibrated with binding buffer (30m1). 
Post (NH4)SO4 concentrated antibody (15m1) pre-filtered through 0.45tm and 
0.2gm filters was double diluted with binding buffer and applied to the column. 
The column was washed with binding buffer (SOml). 
Eluting buffer was applied (1 Oml) and fractions (2m1) were collected with the 
addition of neutralising buffer (200 p1). 
The fractions were collected and analysed monitored spectrophotometrically at 
280nm. 
The peak fractions were pooled and dialysed against PBSlazide (3 x 1 000ml). 
The column was washed with binding buffer (30m1) then 20% ethanol (lOml) and 
stored in 20% ethanol at 4°C. 
SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
SDS-PAGE analysis of purified of purified antibody was performed on a Hoefer 
Vertical Electrophoresis Sturdier SE-41 0 apparatus using the following solutions: 
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12% Resolving Gel Volume/ml 
Water 16.5 
30% Acrylamide Mix 20.0 
1.5MTrispI-18.8 12.5 
10% SDS 0.5 
1 0%Ammonium Persuiphate 0.5 
TEMED 0.02 
5% Stacking Gel Volume/ml 
Water 6.8 
30% Acrylamide Mix 1.7 
1.OMTrispH6.8 1.25 
10%SDS 0.1 
10% Ammonium Sulphate 0.1 
TEMED 0.01 
Antibody was desalted with Amicon-30 concentrators according to the 
manufacturer's specifications and 1 to lOp.g fractions applied per well under 
denaturing conditions. The following low molecular weight markers were also 
applied to the outside wells: 
Marker Molecular WeightlkDaitons 
Phosphorylase B 94 
Albumin 67 
Ovalbumin 43 
Carbonic Anhydrase 30 
Trypsin Inhibitor 20 
a Lactalbumin 14 
The gels were run at a constant current of 20mA (voltage going from 90 to 200V) for 
3 h and developed with coomassie blue stain. 
Antibody Storage 
Purified antibody samples were stored for short periods of time (days or weeks) in 
PBS/azide at 4°C. For long periods of time (months) purified antibody samples were 
stored in PBS/azide at -20°C. 
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General ELISA Protocol 
96 well microtitre plates were coated with CC screen (1 O0il per well with 1 OtgmF 
in coating buffer) at room temperature overnight. 
The plates were washed with PB S/T (5x), shaken and aspirated dry. 
The plates were covered and stored at 4°C until used. 
Anti-CC antibody (1 00 jt1 per well diluted in PBS/T) was applied to the CC coated 
plates and incubated overnight. 
Repeated 2). 
Rabbit anti-mouse antibody/HRP (100il per well at 1/1000 dilution in PBS/T) 
was applied and incubated at room temperature for 2 h. 
Repeated 2). 
TMB substrate (lOOtl per well) was applied and after 30 min incubation at room 
temerature the resultant blue colour was quantified spectrophotometrically at 690nm 
on an ELISA plate reader. 
This ELISA protocol was modified for the following applications: 
Antibody Titre 
As above except 4) Anti-EC antibody (lOOp I double diluted in PBS/T) was applied in 
triplicate at each dilution to CC coated plates and incubated at room temperature 
overnight. 
Inhibition 
As above except 4) Anti-cC antibody dilution that gave approximately 20D at 
690nm was applied (50p1 per well) in triplicate with a range of concentrations of 
inhibitor (50.xl per well in PBS) to CC coated plates and incubated at room 
temperature overnight. 
Isotyping 
As above except 6) Secondary antibody/HRP specific to the different mouse antibody 
isotypes (1gM, IgG1, IgG2 , IgG2 , IgG3, K and ?) were applied (lOOpd per well at 
1/100 dilution with PBS/T) and incubated at room temperature for 1 h. 
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EC/AP Titre 
As above except 1) 96 well microtitre plates were coated with anti-EC antibody 
(lOOjil per well with 10.1gmF' in 100mM NaHCO3 at pH=9.5) at room temperature 
for 1 h. 
Plates were used immediately. 
6C/AP (100ji1 per well diluted to 1/100 then double diluted with PBS/T) was 
applied in triplicate at each dilution to antibody coated plate and incubated at room 
temperature for 2 h. 
Step omitted. 
Step omitted. 
pNPP substrate (lOOpJ per well) was applied and after 30min incubation at room 
temperature the resultant yellow colour was quantified spectrophotometrically at 
405nm with a reference at 450nm on an ELISA plate reader. 
Antibody Affinity 
As above except 1) 96 well microtitre plates were coated with anti-EC antibody 
(100tl per well with l0jig.mi' in lOOmIvI NaHCO3 at pH=9.5) at room temperature 
for 1 h. 
3) Plates were used immediately. 
4)EC/AP (100tl per well double diluted from 1/160 to 1/81920 with PBS/T) was 
applied in triplicate to rows B to D on cC coated plate. PBS/T (lOOpi per well) was 
applied in triplicate to rows E to G on the same plate and the plate incubated for 2 h. 
Step omitted. 
Step omitted. 
cC/AP (50tl per well double diluted from 1/80 to 1/40960 with PBS/T) was 
applied in triplicate to rows E to G. pNPP substrate (100tl per well) was applied in 
triplicate to rows B to D and (50j.il per well at double strength) to rows E to G. After 
30min incubation at room temperature and the resultant yellow colour quantified 
spectrophotometrically at 410nm on an ELISA plate reader. 
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Isoelectric Focusing Gel 
Isoelectric focusing gel was run using Pharmacia Phastgel apparatus with a pre-set 
isoelectric focusing gel and an isoelectric focusing pH 3 to pH 10 calibration kit: 
Protein p1 
Trypsinogen 9.30 
Basic Lentil Lectin 8.65 
Middle Lentil Lectin 8.45 
Acidic Lentil Lectin 8.15 
Basic Horse Myoglobulin 7.35 
Acidic Horse Myoglobulin 6.85 
Human Carbonic Anhydrase 6.55 
Bovine Carbonic Anhydrase 5.85 
b-Lactoglobulin A 5.20 
Soybean Trypsin Inhibitor 4.55 
Amyloglucosidase 3.50 
Anti-cC antibody (2tg) was loaded and the gel run according to the manufacturer's 
specifications. 
Immunoaffinity Column Construction 
Method 1: Coupling to Cyanogen Bromide (CNBr) Activated Sepharose 
Used CNBr activated sepharose 4B purchased from Pharmacia. The following 
buffers were prepared: 
Swelling Buffer: 1mM HC1. 
Coupling Buffer: 200mM NaHCO3 and 500mM NaC1 at pH 8.5-9.0. 
Blocking Buffer: 50mM Tris at pH 8.0. 
Acetate Buffer: 100mM NaOAc and 500mM NaCl at pH 4.0. 
Protocol: 
Anti-cC antibody (11.4mg in 2m1 PBS) was dialysed against coupling buffer (3 x 
500m1) and made upto 6m1 with coupling buffer. 
CNBr activated Sepharose 4B (860mg) was poured onto a glass sinter funnel 
(porosity 4) and washed with swelling buffer (200m1) for l5minThe gel swelled to 
approximately 3 ml. 
The gel was quickly washed with coupling buffer (6m1) and aspirated dry. 
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The gel was transfered to the antibody solution from 1) to give a 2:1 (v/v) 
antibody :gel suspension. 
The suspension was slowly tumbled on an end-to-end mixer for 20 h at 4°C. 
The suspension was filtered and washed with blocking buffer (6m1) and the 
combined filtrate and washing solution was analysed spectrophotometrically at 
280nm for unbound antibody. 
The gel was resuspended in blocking buffer (6m1) and slowly tumbled on an end-
to-end mixer at room temperature for 2 h. 
The gel was poured into a column (12mm x 107mm with porous polyethylene 
discs at top and bottom of gel bed). The column was washed with acetate buffer 
(lOml) and then blocking buffer (lOml). The washing was repeated. 
The column was washed with PBS/azide (lOmi) and stored in PBS/azide at 4°C. 
Method 2: Coupling to Aldehyde Functionalised Agarose 
Used Pierce Immunopure Ag/Ab Immobilization Kit 1. The kit contained: 
Coupling Buffer: 100mM sodium phosphate and 0.05% sodium azide at pH 7.0. 
Quenching Buffer: 1M Tris.HC1 at pH 7.4. 
Washing Buffer: 1M NaCl. 
Reductant: NaCNBH3. 
Pre-swollen aldehyde functionalised agarose pre-packed in a column (12mm x 
107mm with porous polyethylene discs at top and bottom of gel bed). 
Protocol: 
The column was equilibrated with coupling buffer (6m1). 
Anti-SC antibody (28.3mg in 2.5m1 of PBS) was added to the column. The column 
was capped at each end and slowly tumbled on an end-to-end mixer at room 
temperature for 2 h. 
Reductant (200.d, 1M in coupling buffer) was added. The column was slowly 
tumbled on an end-to-end mixer for 2 h and then left standing at room temperature 
for 4h. 
The column was drained and equilibrated with quenching buffer (4ml) and the 
combined eluents analysed spectrophotometrically at 280nm for unbound antibody. 
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Quenching buffer (2m1) and reductant (20041, 1M in quenching buffer) were 
added. The column was slowly tumbled on an end-to-end mixer for 30mm 
The column was washed with washing buffer (4 x 5m1) and PBS/azide (4 x 5m!). 
The column was stored in PBS/azide at 4°C. 
Method 3: Coupling to Prepacked Pharmacia HiTrap Protein-A Column 
Used pre-packed HiTrap Protein-A column from Pharmacia. The following buffers 
were prepared: 
Binding Buffer: 100mM Tris at pH 7.4. 
Coupling Buffer: 200mM Triethanolamine at pH 8.0. 
Crosslinking Buffer: 20mM Dimethylpimelimidate in coupling buffer (made fresh). 
Quenching Buffer: 20mM Ethanolamine in coupling buffer. 
Protocol (all manipulations were carried out by 5 and 20 ml syringes): 
The column was equilibrated with binding buffer (20m1). 
Anti-cC antibody (19.2mg in 20m1 of binding buffer) was slowly passed (3x) 
through the column. 
The column was equilibrated with coupling buffer (20m1). 
Over 45min crosslinking buffer (20m1) was passed through the column. 
Over 5min quenching buffer (5m!) was passed through the column. 
The column was washed with PBS/azide (40m1) and stored in PBS/azide at 4°C. 
Method 4: Coupling to Protein-A Derivatised Agarose 
Used Protein-A coupled to agarose purchased from Pierce. The following buffers 
were prepared: 
Binding Buffer: 3M NaC1 and 1.5M Glycine at pH 8.9. 
Coupling Buffer: 200mM Triethanolamine at pH 8.0 
Crosslinking Buffer: 20mM Dimethylpimelimidate in coupling buffer (made fresh). 
Quenching Buffer: 20mM Ethanolamine in coupling buffer. 
Protocol: 
1) The gel (2m1) was suspended in binding buffer (30m1), spun (30G, 5mm) and the 
supernatant discarded. This was repeated twice. 
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Anti-EC antibody (13.2mg in 4m1 PBS/azide) with binding buffer (lOmi) was 
added to the gel and slowly tumbled on an end-over-end mixer at room temperature 
for 1 h. 
The suspension was spun (30G, 5mm) and the pellet resuspended in coupling 
buffer (30m1). The washing was repeated twice and the washings combined and 
analysed spectrophotometrically at 280nm for unbound antibody. 
Crosslinking buffer (30m1) was added and the suspension slowly tumbled on an 
end-to-end mixer at room temperature for 1 h. 
The suspension was spun (30G, 5mm) and the supernatant discarded. 
Quenching buffer (30m1) was added and the suspension slowly tumbled on an end-
to-end mixer for 5mm 
The gel was poured into a column (12mm x 107mm with porous polyethylene 
discs at top and bottom of gel bed) and washed with PBS/azide (50m1). The column 
was stored in PBS/azide at 4°C. 
The above method was also used with the following modifications: 
Modified Protocol 1: As above except: 
Step omitted. 
The suspension was spun (30G, 5mm) and the supernatant discarded and the pellet 
resuspended in coupling buffer (30m1). The washing was repeated twice. 
Crosslinking buffer (30m1) was added and the suspension slowly tumbled on an 
end-to-end mixer at room temperature for 1 h. 
Anti-SC antibody (9.8mg in 4m1 PBS/azide) with binding buffer (lOmi) was added 
to the gel and slowly tumbled on an end-over-end mixer at room temperature for 1 h. 
The suspension was spun (30G, 5mm) and the supernatant analysed 
spectrophotometrically at 280nm for unbound antibody. 
Modified Protcol 2: As above except: 
2) Anti-SC antibody (7.1mg in 4m1 PBS/azide) with binding buffer (lOmi) was 
equilibrated with EC (1 p.mol) for 1 h then added to the gel and slowly tumbled on an 
end-over-end mixer at room temperature for 1 h. 
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Method 5: Coupling to Hydrazide Functionalised Agarose 
Used Pierce Immunopure Ag/Ab Immobilization Kit 4. The kit contained: 
Coupling Buffer: 100mM sodium phosphate and 0.05% sodium azide at pH 7.0. 
Oxidation Vial: sodium m-periodate (5mg). 
Desalting Column. 
Pre-swollen hydrazide functionalised agarose pre-packed in a column (12mm x 
107mm with porous polyethylene discs at top and bottom of gel bed). 
Protocol: 
Anti-sC antibody (31.1mg in 3m1 PBS/azide) was concentrated to 1 ml by 
Amicon-30 to the manufacturer's specifications. 
The desalting column was equilibrated with coupling buffer (8m1) and the 
antibody solution (imi) was desalted through the column. The antibody containing 
fractions were analysed specrophotometrically at 280nm. 
The antibody solution (3 ml) was added to the oxidation vial and gently swirled for 
5min The vial was incubated at room temperature for a further 30mm 
The desalting column was equilibrated with coupling buffer (1 5ml) and the 
antibody solution (3m1) desalted through the column. The antibody containing 
fractions were analysed spectrophotometrically at 280nm. 
The antibody solution (5m1) was added to the gel and slowly tumbled on an end-
to-end mixer at room temperature for 16 h. 
The column was drained and washed with coupling buffer (6m1) and the eluents 
analysed spectrophotometrically at 280nm for unbound antibody. 
The column was washed with PBS/azide (20m1) and stored in PBS/azide at 4°C. 
General Protocol for the Use of Immunoaffinity Columns to Trap EC Antigens 
Storage buffer drained from column. 
Column conditioned with 500mM NaCl (2 x column volume). 
Column equilibrated with cold PBS (3 x column volume). 
sC antigen in cold PBS (25% of the column volume) was added to column and 
allowed to enter gel bed. 
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Cold PBS (5% of the column volume) was added to the column and allowed to 
enter the gel bed. 
The column was capped at the bottom and cold PBS (imi) added. The column was 
capped at the top. 
Incubate for 1 h at room temperature. 
Caps were removed. Wash column with cold PBS (8 x column volume). 
Washed column with cold water (4 x column volume). 
Add elution buffer (2 x column volume) and collect fractions. 
Washed column with PBS/azide (5 x column volume). 
Capped column at bottom and add PBS/azide (2m1). Capped column at top and 
stored at 4°C. 
On the first initial trial of the immunoaffinity column all fractions eluting from the 
column were collected. 
Alkylation of the Antibody with Dimethylpimelimidate 
Anti-6C antibody (200 jig) was incubated with dimethyl pimelimidate.HC1 (2ml of 10 
to 20mM in 200mM triethanolamine buffer at pH 8.0) in Amicon microcon-30 at 
room temperature. After 45 min the vials were spun (3,500G. 5mm) and PBS (imi) 
added. The vial was inverted and spun (3,500G, 5mm). The antibody solutions were 
analysed by ELISA titration with an antibody solution treated identically with 
dimethyl pimelimidate absent. 
Alkylation of the Antibody with Acetic Acid 
Anti-SC antibody (200 jig) was incubated with a solution of acetic acid (100mM) and 
1 -ethyl-3 -(3 -dimethylaminopropyl)carbodiimide.HC1 (5mg) in MES buffer (2ml) 
adjusted to pH 6.0. The mixture was incubated overnight at 40°C. The antibody 
solution was analysed by ELISA titration with an antibody solution treated 
identically with 1 -ethyl-3 -(3 -dimethylaminopropyl)carbodiimide absent. 
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The Use of Amicon Concentators to Trap EC Antigens 
Protocol: 
cC oligonucleotides (mM to 10tM in lOOp! PBS) and anti-EC antibody (7jM in 
lOOtl PBS) were added to Amicon microcon-100 and incubated for 16 h at 4°C. 
The Amicon microcon- 100 were spun (4,000G, 1 5mm) and the eluent collected. 
PBS (200tl) was added to the Amicon microcon-100 and spun (4,000G, 15mm) 
and the eluent was collected. 
8M Urea (200pJ) was added to the Amicon microcon- 100 and incubated at room 
temperature for 2 h. 
The Amicon microcon-100 was spun (10,000G, 15mins) and the eluent collected. 
PBS (20Otl) was added to the Amicon microcon-100 with the filter reversed and 
spun (4,000G, 1 Smins). The eluent was collected. 
The collected eluent fractions were analysed using the dot blot protocol described 
above. 
Preparation of 5 ,6-dihydro-5-oxo-6-D-2' deoxyribofuranosylimidazo- [1,2-cl - 














cC monophosphates and bisphosphates were prepared using the oligonucleotide 
synthesis methodology described above but incorporating a phosphate addition 
monomer supplied by Cruachem. Purification was achieved by reverse phase HPLC 
as above and desalting by gel filtration (G25 Sephadex) chromatography. The 
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appropriate fractions were collected and freeze dried to obtain the title compounds as 
white solids, cC monophosphate (2.0jimol), 	([21-12]-1320) 0.269 (1P, s, P V);  
max(1 20)1'11m 292(shoulder), 281(shoulder) and 272; m/z 330.05 169 (M-1; Caic. for 
C11H13N307P, 330.04911), EC bisphosphate (2.86umol), d([2H2]-D2O) 2.423 (2P, d, 
pV); 
m (H20)/nm 292(shoulder), 281 (shoulder) and 272; m/z 412.03115 (M+1+; 
Calc. for C11H15N3010P, 412.03110). 
Analysis and Quantification of cC in Immunoaffinity Column Eluents 
Method 1: When the antigen is an cC oligonucleotide 
Collected fractions were aspirated dry, votexed with PBS (20i.il) and analysed using 
the dot blot protocol described above with standard dilutions of EC oligonucleotide. 
Method 2: When the antigen is an PC nucleoside 
Collected fractions were aspirated dry, vortexed with PBS (SOjil) and analysed using 
the collected fractions as competitors in the inhibition ELISA protocol described 
above with standard dilutions of cC nucleoside. 
Method 3: When the antigen is an cC monophosphate 
Collected fractions were freeze dried and vortexed with water (20p1). EC 
bisphosphate (lOnmol to lOpmol) was added. The samples were analysed by CZE on 
an Applied Biosystems Model 270A Capillary Electrophoresis system with Microgel 
capillaries using 75mM Tris-phosphate with 10% methanol at pH 7.6 elution buffer. 
The on-line detector was set at 272nm with the loading voltage at -5kV, temperature 
at 30°C the running voltage at -15kV and the sample uptake time at 5 to 30s. Sample 
runs were recorded on a chart recorder set at: chart speed lcm.min', attenuation 16, 
offset 5 and peak threshold 1000. 
Incubation of Double Stranded DNA with Chioroacetaldehyde 
DNA duplex d(GCGCTTAAGCGC)2  (1mg freeze dried) was dissolved in PBS 
(500p1) and an aliquot (50tl) removed. Chioroacetaldehyde (50.il diluted 1/10 with 
PBS from a 50% stock solution in water) was added and the solution incubated at 
370C. Aliquots (50t1) were removed at the following time intervals: t1, 5, 10, 15, 
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30, 60 min The aliquots were immediately desalted by NAP5 gel filtration 
chromatography to the manufacturer's specifications eluting with enzyme digest 
buffer. The samples (lml) were incubated at 80°C for 90 min and cooled to 37°C. 
Snake venom phosphodiesterase I (0.05 units) was added to each sample and 
incubated for 24 h at 37'C. The samples were purified by immunoaffinity 
chromatography as described above and the CC present quantified by method 3, 
adding CC bisphosphate (5nmol). 
This experiment was repeated using a 100 fold dilution of chloroacetaldehyde 
Incubation of Single Stranded DNA with Chioroacetaldehyde 
As for the double stranded DNA incubation with chloroacetaldehyde but using single 
stranded DNA d(ACTCATGCCGGG) (ling freeze dried) and using CC biphosphate 
(lOnmol, 5nmol when chloroacetaldehyde diluted 100 fold) in analysis method 3. 
Large Scale DNA Digestion to Nucleotides 
Herring sperm DNA (2.21g freeze dried) was dissolved in enzyme digest buffer 
(1 Omi) and snake venom phosphodiesterase I (1 unit) added. The thick, brown 
suspension was incubated for 96 h at 37°C afterwhich the suspension became slightly 
turbid. Trypsin (lOOp.g) was added and incubated for 24 h at 37°C. Soybean trypsin 
inhibitor (1 00tg) was added to the resulting clear solution and incubated for 2 h at 
37'C. The solution was freeze dried to yield a brown powder. 
CZE Analysis of Oligonucleotide Purity 
Samples of puified oligonucleotides were analysed by CZE as described above. 
31P NMR of Oligonucleotides 
DNA duplexes (approximately 450nmol freeze dried) were dissolved in 5mM 
KH2PO4  and 100mM KC1 at pH 7.0. The samples were freezed dried in Eppendorf 
vials. The samples were dissolved in D20 and 31P NMR spectra recorded at 9.4T on a 
Bruker AM400 spectrometer using a 5mm phosphorus probe, and at 298K. The 
aquisition time was 1 .708secs. with an additional delay of 1.2s. (recycle time of 
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2.9s.). The 900  pulse width was 1199.04Hz. WALTZ was used for proton 
decoupling, centred at 4.lppm. Free induction decays were zero-filled once and 
apodised with 0.5Hz line-broadening exponential Fourier transformation 
UV Thermal Denaturing Studies of Oligonucleotides 
UV thermal denaturing was performed on a Perkin Elmer Lambda 15 UV/visible 
spectrophotometer equipped with a Perkin-Elmer Peltier block and controlled by an 
IBM PS2 microcomputer running a Perkin-Elmer PECSS2 software package to 
present absorbance versus time melting curves. Single stranded oligonucleotides 
were dissolved in UV melting buffer. Solutions were mixed to give double stranded 
oligonucleotides to give 5jtM to 500nM solutions when made upto 2.5m1 with UV 
melting buffer in a cuvette. UV thermal denaturing runs were performed in triplicate 
at 5 different concentrations at a linear gradient of 1°C.min' from 10°C to 80°C at 
260nm. The absorbance at 80°C was recorded and the concentrations of single 
strands determined using excinction coefficients. TCONV3 1 software package was 
used to convert to absorbance versus temperature and Perkin-Elmer PECSS2 
software package to calculate the first derivative and the point of inflection. 
Crystallisations of Oligonucleotides 
The following solutions were made up and filtered through 0.2jtm filters: 
100mM MgC12, 
10mM Spermine.4HC1. 
50% Methylpentanediol (MPD). 
50mM Sodium cacodylate at pH 6.5. 
Pure, desalted and freeze dried DNA was dissolved in sodium cacodylate solution to 
give 50il of a 2mM DNA solution and crystallisation plates made up as follows: 
p1 1 2 3 4 5 6 7 8 9 
Water 9 9 9 9 9 9 9 9 9 
DNA 5 5 5 5 5 5 5 5 5 
MgCl2 X X X X X X X X X 
MPD 5 5 5 5 5 5 5 5 5 
Spermine X X X X X X X X X 
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Where X was a variable quantity. The plates were covered with glass slides and 
sealed with vacuum grease. The plates were incubated at room temperature, 8°C or 
4°C and periodically examined for crystal growth by microscope. 
The Ratio of Double to Single Stranded DNA Analysed by CZE 
Two duplex forming single strands of DNA (5mg/strand) were dissolved in water 
(25m1) and mixed together in the following solutions to make a total volume of4Opi: 
Solution 1 2 3 4 5 6 7 8 9 10 11 
Strandi/pi 25 24 23 22 21 20 19 18 17 16 15 
Strand2/.tl 15 16 17 18 19 20 21 22 23 24 25 
The solutions were analysed by CZE as described above but at a running temperature 
of 25.5°C and using an eluting buffer of 75mM Tris-phosphate at pH 7.6. 
FPLC Analysis and Purification of Oligonucleotides 
Oligonucleotide analysis and purification by FPLC was carried out using a 
Pharmacia GP-250 Plus system with two LKB P-500 pumps equipped with a 
Pharmacia Resourse Q ion exchange column. The eluting buffers used for denaturing 
conditions were: buffer A-lOmM NaOH at pH 12 and buffer B-lOmM NaOH plus 
1.5M NaC1 at pH 12 and for non-denaturing conditions were: buffer A-50mM Tris at 
pH 7.4 and buffer B-50mM Tris plus 1 .OM NaCl at pH 7.4. The following elution 
gradient was used: 
Time/min Flow Rate/mlmin' % Buffer B 
0 3 10 
2 3 10 
20 3 100 
22 3 100 
23 3 10 
25 3 10 
Analytical scale runs were performed at 260nm and 0.5aufs. Preparative scale runs 
were performed at 298nm and 1 aufs. 
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CHAPTER TWO 
Immunochemical Detection of Oligonucleotide Probes 
Labelled with Dansyl Reporter Groups 
Tae a Moose 
"Wee sleeket, cowrin' tim'rous beastie, 
0, what a panic's in thy breastie! 
Thou need na start awa' sae hasty, 
Wi' bickerin' brattle!' 
I wad be laith to nfl an' chase thee, 
Wi' murderin 'pattle! 
I'm truly sorry man's dominion, 
Has broken nature social union, 
An 'justifies that ill opinion, 
Which makes thee startle, 
At me, thy poor, earth-born companion, 
An 'fellow mortal!" 
Robert Burns (November 1785) 
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INTRODUCTION 
It is well established that the macromolecule, DNA, with the exception of 
RNA viruses is the genetic information store for all cellular life. In recent years it has 
been shown that illnesses can be the result of abnormalities in the genetic code, due 
to viral infection or inherited genetic disease. It is now possible to diagnose such 
illnesses by probing genomic DNA for such abnormalities. The ability to synthesise 
and modify oligonucleotides that are complementary to intra-gene sequences has 
allowed the recognition of specific genomic DNA. A variety of methods have been 
employed to modify oligonucleotide probes to enable their detection. 
Labelling synthetic oligonucleotides with radionuclides was the established 
technique. However, this methodology suffers from some serious drawbacks: 
The three commonly used radionuclides, 32P, 35S and 
125j  have short half-
lives, 14.2, 87.4 and 59.6 days respectively, thus diagnostic experiments must be 
rapidly performed after labelling and long term storage is precluded. 
Due to constant radioisotopic decay the intensity of emitted radiation is 
variable resulting in uncertain detection sensitivity. 
The cost of these potentially hazardous materials and their safe handling is 
becoming increasingly prohibitive. 
These factors can outweigh the advantages of the inherent sensitivity of this 
technique thus necessitating the development of cheap, safe and sensitive non-
radioactive labelling methods. 
Non-radioactive Labelling 
Non-radioactive labelling of oligonucleotides is well established and has been 
reviewed in great detail 14,  hence only a brief outline of non-radioactive labelling 
methods will be given here. 
Oligonucleotide probes can be covalently tagged with labels that are 
themselves directly detectable or that promote the indirect binding of a detectable 
molecule. Directly detectable labels include fluorescent dyes which emit a 
quantifiable signal when irradiated or enzymatic labels which produce colourimetric 
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or chemiluminescent signals upon addition of a substrate. Indirectly detectable labels 
bind a protein-enzyme conjugate which is then detected in a second step. Commonly, 
this is an antibody-enzyme conjugate when the label is a hapten or a streptavadin-
enzyme conjugate when the label is biotin (figure 1). 
Target DNNA on membrane. 
Incubate with labelled oligonucleotide probe. 
Labelled oligonucleotide probe hybridises 
to complementary sequence in target. 
\ Incubate with protein 
\nzyme conjugate. 
Detect label. 
Figure 1: The Experimental Steps in Direct and Indirect Labelling Systems 
Labels have been incorporated into oligonucleotides in a number of ways. 
They have been introduced enzymatically by the action of transferase and 
polymerase enzymes on modified nucleotide triphosphates and chemically by 
employing modified phosphoramidite monomers during automated oligonucleotide 
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synthesis. The modifications either include the labels themselves or reactive 
functionalities capable of incorporating labels post-synthetically (figure 2). 
0 	o 
NH 
0 0 0 NO 
II 	II 	II 	/101 o—p—o—p—o—p—o 
I I 
0 0 O 
/ OH 
Polymerase or transferase./ 
\ \Automated DNA synthesis. 	
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Figure 2: Label Incorporation into Oligonucleotides 
Fluorescent dyes such as fluorescein, 7-nitrobenzo-2-oxa-1 ,3-diazole (NBD), 
tetramethylrhodamine and Texas Red (figure 3) have been introduced during 
automated oligonucleotide synthesis via their phosphoramidites5'6 or by post-
synthetically coupling electrophilic dervatives such as N-hydroxysuccinimides7, 
isothiocyanates8 and halides  to amino 














Figure 3: Fluorescent Labels 
The enzymes horseradish peroxidase (HRP) and alkaline phosphatase (AP) 
have been covalently crosslinked to oligonucleotides by a variety of coupling 
methods12 1 5. The signal produced by such enzymes is entirely dependent on the 
choice of substrate. Colourimetric detection is based on enzymatic action converting 
a pale coloured or colourless, soluble substrate into a highly coloured soluble or 
insoluble product. Substrates which produce soluble products are 3,3',5,5'-
tetramethylbenzidine (TMB) with HRP16 and para-nitrophenyl phosphate (pNPP) 
with AP 17. Substrates which produce insoluble products include 3,3'-
diaminobenzidine (DAB) with HRP'8 and 5-bromo-4-chloro-3-indoyl 
phosphate/nitro blue tetrazolium (BCIPINBT) with AP'9 
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Although the fluorescent dyes and HRP and AP via a substrate are directly 
detectable they have disadvantages: 
Experimental conditions such as solvent polarity heat and pH can distort 
fluorescent properties and can denature enzymes. 
The size of these molecules, particularly enzymes may sterically inhibit the 
hybridisation of the probe to the target sequence. 
Fluorescent dyes and detectors are costly and oligonucleotide-enzyme 








Figure 4: Indirect labels 
The strong affinity between biotin (Vitamin H) (figure 4a) and the bacterial 
analogue of avidin, streptavidin, is commonly used in indirectly detectable labelling 
systems. Oligonucleotides have been labelled enzymatically via biotin labelled 
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deoxyuridine20, deoxyadenosine2' and deoxycytidine2' triphosphates, during 
oligonucleotide synthesis via a variety of biotin phosphoramidites2225 and post-
synthetically via N-hydroxysuccinimide26'27, hydrazide28 and azide29 derivatives. 
Detection is accomplished by the secondary binding of a streptavidin-enzyme 
conjugate. The enzyme is commonly either HRP or AP using the colourimetric signal 
production outlined above. As with directly detectable labels, biotin and streptavidin-
enzyme conjugates are expensive and biotin, which is of biological origin can also 
suffer problems with background contamination from the target sample. 
Digoxigenin (figure 4b) is a large terpenoid which when used as a label 
circumvents the background contamination problems of biotin30. It has been 
incorporated into oligonucleotides enzymatically 31, during automated synthesis and 
post-synthetically 32.  This label is detected immunochemically by anti-digoxigenin 
antibodies conjugated to AP. The drawbacks with the use of digoxigenin as a label 
are its expense, instability to normal automated oligonucleotide synthesis conditions 
and multiple functionality, making it difficult to derivatise. 
The potential of the 2,4-dinitrophenyl (DNP) group (figure 4c) as an 
oligonucleotide label has only recently been realised3337. DNP's properties as a 
cheap, highly coloured, chemically simple, extremely immunogenic small molecule 
make it very attractive as a non-radioactive label. As the molecule is not found in 
vivo the background signal is low and high affinity anti-DNP antibodies are readily 
available. Detection is either by anti-DNP antibody-enzyme conjugates or by a two 
step anti-DNP antibody then anti-antibody-antibody enzyme conjugate system 
(figure 5). 
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One step immunochemic 
Two step immunochemical detection. 
Figure 5: Immunochemical Detection 
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Antibodies 
The Immune System 
The immune system has developed to protect the host from attack by 
invading micro-organisms, parasites and cancer cells38. The mechanisms of innate 
and acquired immunity respond in tandem to foreign bodies whilst tolerating 
substances found in the host tissue39. Innate immunity is mediated by macrophages, 
natural killer cells and the activation of compliment. It is non-specific and non-
adaptive, therefore unable to enhance the immune response upon repeated 
exposure 40. Acquired immunity is dependent on cellular mechanisms capable of 
memorising exposure and eliciting specific responses 41. 
Acquired Immunity 
The mechanisms of acquired immunity are dependent on the recognition of 
foreign bodies by T and B lymphocytes via receptors on their surface42. The immune 
system is capable of synthesising vast repertoires of receptors and binding sites 
(>108) due to rearrangement of its genes and gene reading frames and also through 
point mutations. In this way highly specific binding sites are created43. 
Upon entering the host, foreign bodies, or antigens are recognised, engulfed 
and degraded into fragments by Antigen Presenting Cells (APC). The fragments are 
displayed on the cellular surfaces as complexes with glycoproteins. These Major 
Histocompatibility Complexes (MHC) bind specific T cell receptors activating 
InterLeukin (IL) growth factors which signal T cell proliferation (figure 6). As the 
binding of T cells is specific to the antigen-glycoprotein complex only a small 
fraction of the total T cell population is activated ie. only those capable of 
recognising the antigen. T cells then stimulate mechanisms to destroy the invading 
organism and participate in B cell proliferation44. 
B cells also bear antigen specific receptors which on binding the antigen are 
withdrawn and degraded. The antigen is presented as a MHC by the B cell, binding 
antigen specific T cells. T cell binding activates interleukin production, stimulating B 
cell differentiation and proliferation45. The majority of daughter B cells produce large 





Antigen enters host. 
Antigen is engulfed by APC. 
APC 
	
) < > 	 APC 
APC attacks antigen 







14 	 APC and Tcell bind. 





Antigen enters host. 
Bcell binds antigen. 
Antigen 	 %- Bcell Antigen 
Bcell attacks antigen. 
Antigen presented as M}IC. 
8~B:cell and Tcell bind. 	 BcelI 







 K CBrnernory cell 
\ells proliferate. 
Figure 7: B Cell Mediated Immunity 
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cells capable of speedy reactivation of the immune system in reponse to further 
exposure to the antigen 46  (figure 7). 
During differentiation, the B cells which bind most strongly to the antigen 
proliferate preferentially thus increasingly higher affinity antibodies are selected. 
There are five major classes of antibody IgA, IgD, IgE, IgG and 1gM although only 
two, IgG and 1gM, are present in large amounts within the plasma. Initially the 
immune system produces antibodies of the 1gM class. However, these are often 
quickly superseeded by higher affinity antibodies of the IgG class when class 
switching takes place47. Initially the immune system responds to antigen presentation 
by synthesising antibodies of the 1gM isotype. These are superseeded by mature IgG 
antibodies which have undergone successive cycles of gene recombination and 
mutation, selecting antibody binding sites of increasing affinity and specificity48. The 
biological functions of these antibodies are primarily antigen binding, coating it in an 
inactivating layer and promoting phagocytosis and compliment activation 49. 
Production of Antibodies 
In recent years the acquired immune system has been artificially harnessed to 
produce specific biochemical tools, antibodies with tailor-made binding sites. 
Initially antibodies were produced by immunising mammals with the 
immunogen of interest. After boost immunisations the animals could be bled and the 
antibodies purified from the sera. This produced polyclonal antibodies. Most antigens 
have multiple antigenic determinants or epitopes, the regions where the antibody 
binds. These can be recognised by receptors on different B cells. Thus antibodies of 
different epitope specificities are generated, in a polyclonal response. Polyclonal 
antibodies are of variable affinity and specificity especially when impure 
immunogens are used51. 
Hybridoma technology was developed to allow the production of antibodies 
from a single B cell and these were termed monoclonal antibodies. These antibodies 
are advantageous in that they are of single determinant specificity and can be selected 
in terms of their affinity. This makes them desirable as diagnostic tools as they can 
be selected for their reproducible properties. The principle of the technique centres 
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on isolating mortal B cells from an immunised animal and fusing them with immortal 
myeloma cells creating hybrids of the two. In practice, the fusion process is random 
and a mixture of B cells, myeloma cells and multiple hybrids are formed, only some 
of which produce useful antibodies. These can be isolated by feeding the cells with a 
selective medium containing Hypoxanthine, Aminopterin and Thymidine (HAT). 
Aminopterin inhibits nucleotide biosynthesis and thus poisons cells. However, B 
cells express an enzyme, Hypoxanthine Guanine PhosphoRibosyl Transferase 
(HGPRT) which provides an alternative salvage pathway to nucleotide biosynthesis. 
Cells that express this enzyme survive aminopterin poisoning. Myeloma cells are 
deficient in the HGPRT gene and die in the presence of aminopterin. B cells, due to 
their mortality also decline in number over time thus leaving only cells capable of 
expressing the surviving HGPRT gene product ie. fused B cell-myeloma cells known 
as hybridomas (figure 8). The cells remaining are assayed for production of the 
required antibody and isolated from all the other cells in culture by cloning. This 
selection of hybridomas negates the need for immunogens of high purity51. Cloning 
is a process whereby the cells of interest can be isolated from all the other cells in 
culture. It is essential soon after the positive identification of antibody producing 
cells to reduce the risk of overgrowth by non-secreting cell lines. Cloning is also 
required to ensure monoclonality of the secreting cell lines. 
Cells have been cloned by limiting dilution or in soft agar. Cloning by 
limiting dilution involves successive dilution of the selected hybridoma cell 
population into wells within culture plates resulting in a number of wells containing 
single cells. Cloning in soft agar separates cells by a solid phase barrier. This method 
often requires an additional reculturing step in liquid medium before antibody 
production can be screened. In practice several rounds of cloning are required before 
a monoclonal cell line has been achieved. 
Hybridomas rarely survive culturing in isolation. However, it is possible to 
increase the efficiency of cell survival and growth by a factor of 10 by the addition 
of 'feeder cells"52. The reasons for this are not understood but it is possible that 
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proliferation53. Cells that have been used as feeders are thymocytes, spleenocytes and 
peritoneal cells51. 
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Figure 8: Cell Fusion 
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AIMS OF THE PROTECT 
In order to provide an alternative to the biotin and digoxigenin 
oligonucleotide labelling systems and to complement the existing DNP system, a 
further potential labelling group was studied. The dansyl group (figure 4d) has been 
used in the past to label amino acids, proteins and oligonucleotides53'54. This 
approach has only made use of the fluorescent properties of this group. However, 
dansyl is highly immunogenic and immunochemical detection of dansyl labelled 
probes could provide an extremely sensitive reporter system. Dansyl labelled 
oligonucleotides have been synthesised, as has the DNP system, for immunochemical 
detection 55.  The aim of this project was to raise a cell line secreting monoclonal anti-
dansyl antibodies and to evaluate and compare this system to the DNP system. 
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RESULTS AND DISCUSSION 
Preparation of Dansyl Immunogen 
In order to elicit an immune response, the dansyl group was conjugated to a 
larger carrier molecule as, in general, substances of molecular weight below 1000 are 
not immunogenic57. Bovine serum albumin (BSA) was selected as the carrier 
molecule as the numerous lysine residues on the protein's surface can be easily 
functionalised with dansyl chloride (figure 9). BSA is a protein of molecular weight 
of 67,000 Daltons and therefore provokes a large immune response in mice due to the 
large number of potential determinants foreign to the self-configurations that induce 
tolerance within the animal. 
BSA 





Figure 9: Functionalisation of BSA with Dansyl 
The inherent hydrophobicity of dansyl chloride prevented reaction with BSA 
in the aqueous buffer required for the protein, therefore DMSO was added and the 
conjugation mixture warmed to solubilise the reagent. 50% ethanol was used as the 
elution buffer in the subsequent chromatographic step to stop excess dansyl chloride 
precipitating and blocking the desalting column. 
Evidence of dansyl-BSA conjugation was obtained by an obvious change in 
colour of the eluted protein (from colourless to yellow), strong fluorescence when 
irradiated at 320nm and comparison of the IJY absorbance scans of dansyl chloride, 
BSA and the eluted protein in the region 240 to 300nm (figure 10). The eluted 
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Figure 10: UV Absorbance Scans 
Immunisation 
The dansyl-BSA conjugate was emulsified with Freund's Complete Adjuvant 
for primary immunsation. This contains a suspension of killed mycobacteria in 
mineral oil which potentiates the immune response58. Freund's Incomplete Adjuvant, 
containing no mycobacteria, was used for the secondary immunisation. 
The conjugate was used as the 50% ethanol storage solution. In hindsight, 
removal of ethanol would have been advantageous as it is an immune system 
surpressant59. It was also observed to be harmful to immunised animals as a number 
of older mice died after immunisation with this solution in separate experiments. 
Two mice (A and B) were immunised and boosted pre-fusion with dansyl 
immunogen. 
Fusion 
The fusion protocol used was developed at Shell Research Ltd. by Dr. Paul 
Aston and was based on the methods of Kohler and Milstein 60  and Galfre et a161. 
This involved blending splenocytes isolated from the spleens of the immunised mice 
with myelomas in ratios of between 10:1 to 1:1 splenocytes:myelomas. Next, the 
controlled addition of the fusion agent, PolyEthylene Glycol (PEG) causes the 
cellular membranes to fuse and multinuclear cells to form. During post-fusion 
cellular division, the nuclei of these so called heterokaryons fuse and the resulting 
daughter hybridoma cells possess a share of the genetic material62. These cells were 
cultured in media containing HAT for 14 days to isolate the viable hybridomas. Two 
fusion experiments were undertaken using a spleen from each mouse. Each fusion 
was divided into 360 wells in 6 culture plates. 
Bleed Assay 
During the period of HAT culture, blood removed from the mice was 
analysed to assess the titre of anti-dansyl antibodies circulating in the animals prior 
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Sera were isolated from red blood cells by centrifugation and double diluted 
across microtitre plates coated with dansyl screen. 
Dansyl screen was prepared in the same manner as dansyl imniunogen, 
replacing BSA with Chicken Gamma Globulin (CyG). As the immune system 
produces antibodies to the immunogen as a whole, many serum antibodies have 
epitope specificity to determinants on BSA, not to the dansyl group. Using dansyl 
screen removes many BSA-like determinants thereby helping to provide a clearer 
representation of anti-dansyl titre. 
An Enzyme Linked ImmunoSorbent Assay (ELISA) revealed quantifiable 
titres of reactivity in the sera towards the dansyl screen (figure 11 and table 1). 
-.- Mouse A 
- Mouse B 
Figure 11: Antibody Titre in Mouse Bleeds 
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To further establish specificity within the sera towards the dansyl group a 
competitive ELISA using ammonium dansylate as an inhibitor was performed. 
Mouse Bleeds Titre IC50 with Ammonium Dansylate/p.M 
A 1/700 7.5 
B 1/250 2.5 
Table 1: Reactivity of Mouse Bleeds to Dansyl 
Dansyl chloride could not be used here as it is insoluble in the aqueous buffer 
required by ELISA. Therefore, it was converted to the ammonium salt of the 
suiphonic acid by reaction with ammonium hydroxide (figure 12). The ELISA 
revealed that the sera reactivity to dansyl immobilised on the microtitre plate could 
be reversed by dansyl in solution (figure 13, table 1). 
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Figure 13: Antibody Specificity to Ammonium Dansylate in Mouse Bleeds 
Screening of Fusion Plates 
14 days post-fusion the 6 culture plates from each fusion were assayed for 
anti-dansyl antibody production. Medium was transfered from the culture plates to 
microtitre plates coated with dansyl screen. ELISA revealed many positive wells 
from both fusions. A total of thirty-five and thirty-two wells were chosen from 
fusions A and B, respectively. The selection criterion was a positive reading six 
times greater than that of the background. Further examination by competitive 
ELISA using ammonium dansylate identified seven wells with specificity to the 
dansyl group for cloning, three wells from Mouse A and four wells from Mouse B 
(tables 2 and 3). On the basis of these results it appeared that the cell fusion using the 
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Positive Wells in 
Initial Screening 





3 D7 7 No 
3 F2 25 Yes 
3 F4 7 No 
3 G5 22 Yes 
3 Gil 42 Yes 
Table 2: Screening of Fusion Wells from Mouse A 
Fusion Plate 
Number 
Positive Wells in 
Initial Screening 





1 C7 45 No 
1 E8 18 No 
2 B2 32 No 
2 F6 31 No 
3 D10 70 Yes 
3 FlO 78 Yes 
5 B9 82 Yes 
5 E2 36 No 
5 F6 43 No 
5 F8 43 No 
5 F9 Si Yes 
6 B7 27 No 
Table 3: Screening of Fusion Wells from Mouse B 
Cloning 
Cloning was achieved by the limiting dilution method. Thymuscytes isolated 
from murine thymus lobes were the feeder cells of choice and supplemented the 
hybridoma cell population at limiting dilution. The hybridoma lines were screened 
and cloned twice sucessively before monoclonality was confirmed (tables 4 and 5). 
Cell lines were assigned a code which denoted the line's lineage from mouse, fusion 
well and cloning wells. The positive wells containing the lowest number of 
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individual clones which showed the greatest antibody titre were selected for 
recloning. These criterion favour cell lines which produce high affinity antibodies in 
high titre. 
Cell Line Number of Positive Wells Found on 
Screening  
Selection for Recloning 
A3F2 0 0 
A3G5 0 0 
A3G11 9 E4 
B3D1O 3 C7 
B3F1O 13 A7 
B5B9 38 E4 
B5F9 0 0 
Table 4: Screening of First Cloning 
Cell Line Monoclonality 
A3G11E4 Yes 
133D1OC7 Yes 
B3F1OA7 No Clones 
135139E4 Yes 
Table 5: Screening of Second Cloning 
From the seven cell lines chosen from the fusion experiments for cloning, 
four cell lines remained positive after screening. Positive wells were selected for 
recloning on the basis of assumed high affinity and titre. Three of the four cell lines 
were cloned successfully. All the isolated clones of these cell lines gave positive 
results on screening indicating monoclonality. 
Monoclonal Cell Lines 
The cell lines A3G1 1E4, B31)1OC7 and B5139E4 were characterised in detail 
to ascertain the cell line most suitable for the non-radiactive labelling application. 





4) ease of purification. 
Monoclonal 
Cell Line 
Titre IC50 with 
Ammonium 
Dansylate/nM 





A3G11E4 / 950 1gM No No 
133D1OC7 1/16 200 1gM No Yes 
135139E4 1/600 60 1gM Yes Yes 
Table 6: Monoclonal Antibody Characteristics 
Titration of cell culture dilutions by ELISA on dansyl screen coated 
microtitre plates gave the titre at half maximal absorbance (approximately 1 0D650) 
(figure 14 and table 6). These dilutions were used in competitive ELISA with 
increasing concentrations of ammonium dansylate to obtain IC50 values for the 
antibodies (figure 15 and table 6). To select the highest affinity antibody the method 
of Rath et a163 was employed. The IC50 values clearly indicate that cell line135139E4 
has the greatest relative affinity. Important additional criteria are antibody isotype 
and ease of purification from serum proteins. 
Antibody isotype determines the physico-chemical properties of the antibody. 
Antibodies of the IgG isotype are the immunochemical reagents of choice due to 
their high solubility, ease of functionalisation and digestion into smaller, active 
fragments. They also tend to be of higher affinity relative to the larger 1gM isotype 
(IgG molecules are of approximately 170,000 Daltons and 1gM molecules are of 
approximately 900,000 Daltons). 1gM antibodies are prone to flocculation, 
64-68 
insolubility and insusceptiblity to fragmentation with retention of activity 	. An 
isotyping kit containing anti-class and anti-subclass specific antibody conjugates was 
used to isotype the antibodies. All 3 were found to be of the 1gM isotype (table 6). 
This was a disappointing and statistically surprising result as 1gM antibodies only 
constitute approximately 5% of the total serum immunoglobuliulins69. This 
warranted further investigation and the dansyl immunogen was re-examined as it 
may have influenced the immune system response. It is known that epitope density 
influences immunological properties as high hapten:carrier protein ratios can 
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mean hapten:carrier protein ratio. This involved counting the free amino groups on 
the dansyl immunogen and native BSA by labelling the free lysine residues with 
trinitrobenzene suiphonic acid (TNBS) and reading spectrophotometrically at 335nm 
(the absorbance at this wavelength of the dansyl immunogen not exposed to TNBS 
had to be subtracted from that of the dansyl immunogen-TNBS complex as the 
dansyl group also absorbs at 335nm). As may have been anticipated from the 
immunochemical results the hapten:carrier protein ratio was extremely high with 57 
of the possible 61 lysine residues labelled with the dansyl group. 
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Figure 15: Monoclonal Antibody Specificity to Ammonium Dansylate 
The antibody binding proteins, Protein-A and Protein-G, can be immobilised 
on solid supports and provide convenient affinity chromatographic methods to 
separate immunoglobulins from other serum proteins. It has become established that 
only murine antibodies of the IgG isotype bind to Protein-A and Protein-G72. In 
practice, however, many 1gM antibodies will also bind 
73.  Indeed, when cell culture 
media from the two higher affinity antibodies were applied to Protein-A and Protein-
G affinity columns strong binding was observed (table 6). The antibodies could also 
be obtained by elution from the column with acid in pure form. As the levels of 
antibody in the media were too low to detect spectrophotometrically by UV 
absorbance at 280nm, a dot blot assay was performed to detect antibody elution. One 
millilitre fractions were eluted from the column and spotted onto a nitrocellulose 
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membrane. The antibody-containing fractions were visualised by the addition of an 
anti-mouse antibody HR-P conjugate and DAB substrate (figure 16). 
All three monoclonal cell lines were frozen. The B5B9E4 cell line that 
showed the greatest promise in terms of affinity and Protein-A and Protein-G binding 
was maintained, recloned once more to ensure monoclonality and expanded into 
larger culture flasks. This cell line was cultured to provide enough antibody to 
evaluate its use in non-radioactive labelling methodology. 
Application of Monoclonal Cell Line B5B9E4 
A litre of antibody-containing medium was harvested from the cell culture 
and crudely purified by ammonium sulphate salt fractionation. The antibody was 
further purified by Protein-A affinity chromatography to yield 1 750j..tg of anti-dansyl 
antibody. Antibody activity was ascertained by ELISA titration. 
The application requires the antibody to recognise the dansyl group in the 
presence of large excesses of DNA. Therefore, it was important to establish no cross-
reactivity of the antibody towards nucleosides. Competitive ELISA using a mixture 
of dA, dC, dG and T at lmgmr' of each revealed no detectable inhibition of anti-
dansyl antibody binding. 
3 dansyl labelled oligonucleotides had previously been synthesised using a 
dansyl phosphoramidite monomer compatible with automated oligonucleotide 
synthesis54. The labelled oligonucleotides bore 1, 3 and 5 dansyl groups at the 5' end. 
5 fold dilutions from a 20j.tM solution of these dansyl labelled oligonucleotides were 
applied along with unlabelled, control oligonucleotide to nylon membrane and fixed 
by UV irradiation. A two step anti-dansyl antibody then anti-mouse antibody HRP 
conjugate dot blot assay revealed detection limits of 2 picomole, 80 femtomole and 
400 femtomole for the oligonucleotides bearing 1, 3 and 5 dansyl groups respectively 
(figure 17). 
A similar assay comparing the detection limits of the dansyl labelled 
oligonucleotides to identical oligonucleotides bearing 1, 3 and 5 terminal DNP 
groups was undertaken. 20 fold dilutions from a 160.tM stock solution were applied 
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Figure 17: Dot Blot of Anti-dansyl Antibody 
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picomole, 200 femtomole and 4 picomole for oligonucleotides bearing 1, 3 and 5 
dansyl groups respectively. However, the DNP system exhibited far higher 
sensitivity with detection limits of 200 femtomole, 10 femtomole and 200 femtomole 
for oligonucleotides labelled with 1, 3 and 5 DNP groups respectively. 
This was disappointing as it had been hoped that the anti-dansyl system 
would display as good if not better limits of detection than the anti-DNP system. The 
difference is undoubtably due to the relative affinities of the anti-dansyl and anti-
DNP antibodies, the anti-DNP antibody being superior. 
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CONCLUSIONS AND FUTURE WORK 
It is clear that a new, higher affinity anti-dansyl antibody is required to make 
this system of antibody mediated non-radioactive labelling viable. As antibodies of 
the IgG isotype tend to be of higher affinity a new immunogen that "selects" for an 




All chemicals, buffer tablets, enzyme substrates and Adjuvants were obtained from 
Sigma. All cell culture media and hybridoma reagents were obtained from Gibco 
with the exception of polyethylene glycol (PEG) from Sera-Lab. Cell culture 
plasticware was obtained from Costar. Microtitre plates were obtained from Nunc. 
Sterile syringes were obtained from Becton Dickson and sterile needles from 
Sherwood Medicals. Secondary antibody horse radish peroxidase (HRP) 
conjugated rabbit anti-mouse immunoglobins were obtained from Dakopatts. 
Antibody isotyping kit was obtained from Sera-lab. Hibond nylon and 
nitrocellulose membranes were obtained from Amersham. Protein-A and Protein-G 
affinity chromatography columns plus buffers were obtained from Pierce. PD 10 
columns were obtained from Pharmacia. Pyrogen-free, reverse osmosis purified 
water was used throughout. 
Buffers, Cell Culture Media and Substrates 
N-morpholinoethanesulphonic acid (MES): 100mM N-morpholinoethanesulphonic 
acid buffered to pH=6.0. 
Phosphate buffered saline pH=7.4 (PBS):lOOmM phosphate and 50mM sodium 
chloride tablets dissolved in water (1 tablet per 200m1). 
RPMI: RPMI 1640 with glutamax. 
RPMI/PS: RPMI with penicillin (200U/ml) and streptomycin (200.1g/m1). 
10% complete media: RPMI/PS with 10% (v/v) fetal calf serum, 2mM sodium 
pyruvate and amphotericin B deoxycholate (2.5pgIml). 
5% complete media: as 10% complete media with 5% (v/v) fetal calf serum. 
10% complete media/HAT: 10% complete media with lOOj.iM hypoxanthine, 
40uM aminopterin and 16tM thymidine. 
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10% complete media/HT: 5% complete media with 1 00.iM hypoxanthine and 
1 6tM thymidine. 
10% DMSO/myoclone: 10% DMSO (v/v) in myoclone. 
Binding buffer: 100mM Tris at pH 8.5. 
Eluting buffer: 100mM Glycine at pH 2.7. 
Neutralising buffer: 1M Tris at pH 9.0. 
Phosphate buffered saline/Tween 20 (PBS/T): PBS with 0.05% (w/v) Tween 20. 
Coating buffer: 15mM sodium carbonate, 35mM sodium hydrogen carbonate 
buffered to pH 9.5. 
PBS/azide: PBS with 0.02% (w/v) sodium azide. 
Blocking buffer: PBS/T with 10% (w/v) skimmed milk. 
Tetramethylbenzidine (TMB) substrate: 3,3' ,4,4' -tetramethylbenzidine liquid 
substrate system containing chromogen, buffer and hydrogen peroxide. 
Diaminobenzidine (DAB) substrate: 3,3' -diaminobenzidine tetrahydrochioride 
tablet plus urea hydrogen peroxide tablet dissolved in water (1 5m!). 
Instrumentation 
'H NMR specra were recorded on a Bruker WP-200 (200.130MHz) spectrometer. 
'3c NMR spectra were recorded on a Bruker WP-200 (50.320MHz) spectrometer. 
Positive ion Fast Atom Bombardment mass spectra were recorded on a Kratos 
MS50 TC spectrometer using a 3-nitrobenzyl alcohol matrix (3-NOBA). UV 
spectra were recorded on a Perkin-Elmer Lambda 15 ultraviolet-visible 
spectrophotometer. JR spectra were recorded on a Bio Rad FTS-7 Fourier 
transform spectrometer controlled by a Bio Rad SPC 3200 microcomputer. ELISA 
plates were read on a Molecular Devices Vmax kinetic microplate reader 
incorporating the Softmax software package. 
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Preparation of Dansyl Immunogen 
BSA (10mg) was dissolved in MES (2m1) and warmed to 37°C. Dansyl chloride 
(20mg) dissolved in DMSO (2m1), was added dropwise to the BSA solution and 
the mixture incubated at 37°C. After 72 h the product was purified on PD1O 
columns to the manufacturer's specifications, equilibrating and eluting with 50% 
ethanol. The conjugate was stored in 50% ethanol at -20°C until used. 
Characterisation of Dansyl Immunogen 
Dansyl immunogen (lml of 750 jig/mi in 50% ethanol) was warmed to 40°C. 4% 
sodium hydrogen carbonate (I ml) and 0.1% trinitrobenzene suiphonic acid (I ml) 
were added and the mixture incubated at 40°C. After 2 h 10% SDS (I ml) and 1M 
HCI (500p1) were added. BSA (imi of 750j.tg/mi in 50% ethanol) was treated 
identically and the absorbance of both solutions read at 335nm against a blank of 
50% ethanol treated as above. 
Preparation of Dansyl Screen 
As for the dansyl immunogen replacing BSA with CyG. 
Ammonium 5-dimethylamino-1-napthalenesulphonate (ammonium dansylate) 
ONH4 
o=s=o 
5-dimethylamino-1-napthalenesulphonyl chloride (525mg, 1 .95mmol) was added 
to conc. NH40H (lOOmi) and stirred at room temperature for 96 h. The solution 
was concentrated in vacuo to yield the title compound as a pale yellow solid 
(481mg, 1.90mmol, 98%). Rf (solvent system DCMI methanol 9/1), 0.15; 
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H([2H6]-DMSO) 8.64-7.62 (6H, m, 4 napthalene H), 3.19 (6H, s, N-Me2) and 2.50 
(41-1, s, NH4 4 ); 6C([2H6]-DMSO) 151 (C), 140 (C), 129 (C), 129 (CH), 128 (CH), 126 
(CH), 124 (CH), 120 (CH), 115 (CH) and 45 (CH3); omax(fium)/Cm' 3320 (NH44), 
1640 (NMe2), 1140 and 1183 (S02-0); ?.m (water)/nm 214,252 and 281; mlz (FAB) 
C12H13NO3S found: 251.06325 calculated: 251.06162. 
Immunisation Protocol 
Dansyl immunogen (100tl of 750j.ig/ml in 50% ethanol) was emulsified with 
Freund's Complete Adjuvant (400d). 3 month old, female Balb/c mice (2) were 
immunised subcutaneously at the knape of the neck (200.i1/mouse). After 21 d boosts 
were administered as above replacing Freund's Complete Adjuvant with Freund's 
Incomplete Adjuvant. Pre-fusion boosts were administered 3 d prior to fusion with 
dansyl immunogen (30p.1 of 750j.xg/ml in 50% ethanol) added to PBS (200j.il), 
injecting lOOpiper mouse via the peritoneum and mid-dorsal tail vein. 
Pre-fusion Bleed 
Mice under anaesthesia were bled via sterile pasteur pipette from the retro-orbital 
plescus. After sufficient blood (approx. 500jtl) had been obtained the pipette was 
removed and the blood transfered to an eppendorf vial. The blood was spun (1500G, 
30mins) separating serum from red blood cells. The serum was removed and stored 
at -20°C until analysed. 
Splenocyte Preparation 
3 d after administration of the pre-fusion boosts, mice were sacrificed by ether 
anaesthesia and cerebral dislocation. Mice were showered with 50% IPA and slit 
open along the abdomen towards the chest with sterile scissors to reveal the spleen. 
Sterile scissors and forceps were used for the splenectomy and the organ was placed 
into cold RPMI (lOmi). The spleen was transfered to a laminar flow hood and placed 
on a sterile petri dish. Residual fatty tissue was trimmed away and a 
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superficial longitudinal incission made along the spleen. Splenocytes were ejected 
by injecting RPMI (2 x lOmi) into the spleen with 25 gauge needles, repeatedly 
puncturing the surface. The cell suspension was spun (500G, 5m) and the 
supernatant discarded. The pellets were resuspended in RPMI (20m1). 
Myeloma Preparation 
Sp2 myeloma cells maintained at 60-70% growth in 10% complete media (4 x 
30m1) in a CO2 incubator at 37°C was suspended and spun (500G. 5m). The 
supernatant was discarded and the pellets were resuspended in splenocyte 
suspension (20ml) prepared as above. 
SplenocytefMyeloma Cell Fusion 
The day before cell fusion, the following were prepared in syringes and stored 
overnight in a CO2 incubator at 37°C: RPMI/PS (2 x lOmi), RPMI/PS (1 x 20m1), 
PEG (6 x 300t1), RPMI/PS (6 x lOmi), 10% complete media (6 x 6ml) and 10% 
complete media/HAT (200m1). The splenocyte/myeloma suspension (20m1) 
prepared above was divided into 6 equal aliquots and spun (500G, 5m). The 
supernatant was discarded and the pellets drained. The pellets were agitated with 
25 gauge needles before dropwise addition of PEG (300t1 per pellet) over 30 s. 
RPMI (lOmi per pellet) was immediately added dropwise over 60 s. The 
suspensions were spun (500G, Sm) and the supernatants discarded. The pellets 
were resuspended in 10% complete media (6m1 per pellet) and transfered to the 
inner 60 wells of a 96 well cell culture plate (100d per well). 10% complete 
media/HAT (100 ji1 per well) was added and the plates placed in a CO2 incubator at 
37°C. 
Thymocyte Preparation 
On the day of cloning a greater than two month old, Balb/c mouse was sacrificed 
by ether anaesthesia. The mouse was opened from the abdomen, through the 
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ribcage to the neck with sterile scissors exposing the thymus lobes. The thymus 
was removed with sterile scalpel and forceps and placed into cold RPMI (1 Omi). 
The organs were transfered to a laminar flow hood and placed on a sterile petri 
dish. Residual fatty tissue was trimmed away and RPMI (lOmi) added. 
Thymocytes were released by teasing the thymus lobes with sterile forceps. The 
thymocyte suspension was spun (500G, 5m) and the supernatant discarded. The 
pellet was resuspended in 10% complete media and thereafter the viable cells could 
stored in the CO2 incubator at 37°C for a maximum of 5 d. 
Cell Cloning 
Hybridoma cells were resuspended from a 96 well culture plate well and added to a 
4 times 1 ml well culture plate. Sufficient suspension was removed for 200 cells per 
lOOmI when added to the thymocyte suspension (4ml) prepared above. Thymocyte 
suspension (500t1) was added to the hybridoma suspension in the 4 well culture 
plate. Hybridomalthymocyte suspension (2.4ml) was transfered (100t1 per well) to 
rows A and B on a 96 well culture plate and thymuscyte suspension (2.4ml) added 
to the original hybridomalthymuscyte sample. This procedure was repeated for 
rows C, D, E, and F. Thymuscyte suspension (800pJ) was added to the original 
hybridomalthymuscyte sample and the remaining (2.4m1) transfered (lOOp.l per 
well) to rows G and H. 10% complete media (100tl per well) was added and the 
plates placed in a CO2 incubator at 37°C. The plates were examined daily for the 
presence of clones taking care not to agitate the cells. After 8-14 d the number of 
clones per well was recorded and the plate screened. 
Cell Culture 
5% complete media was exchanged three times per week. The culture was 
examined for cell growth and at 70% confluency cells were suspended and 
removed with the old medium. The old medium was spun (500G, Sm) and the 
supernatant retained and stored at 4°C or frozen at -4°C. Fresh 5% complete 
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medium warmed to 37°C was added in equal volume and the cells returned to the 
CO2 incubator at 37°C. 
Fusion Culture Maintenance 
At two to three day intervals 10% complete medium/HAT (lOOpi per well) was 
removed carefully from the top of the fusion wells, ensuring no cell agitation. 
Fresh 10% complete medium/HAT (lOOpi per well) was carefully replaced. This 
continued until after the primary screening where 10% complete media/HT was 
replaced. 
Freezing Cell Lines 
Cells were suspended into RPMI (5m1) and spun (500G, 5mins). The supernatant 
was discarded and the pellet drained before addition of 10% DMSO/fetal calf 
serum (3m1). The resuspensed cells were divided into cryotubes (4 x lml) and 
frozen to -70°C before transfer to cryofreeze at -1 8 0°C. 
General ELISA Protocol 
96 well microtitre plates were coated with dansyl screen (lOOpi per well with 
2mgmF' in coating buffer) at room temperature overnight. 
The plates were washed with PBS/T (5x), shaken and aspirated dry. 
The plates were covered and stored at 4°C until used. 
Primary antibody (lOOpi per well diluted in PBS/T) was applied to dansyl 
coated plates and incubated at room temperature overnight. 
Repeated 2. 
Secondary antibody/HRP (lOOpi per well at 1/1000 dilution in PBS/T) was 
applied and incubated at room temperature for 2 h. 
Repeated 2. 
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8) TMB substrate (100 j.il per well) was applied and after 30 in incubation at room 
temperature the resultant blue colour was quantified spectrophotometrically at 
690nm on an ELISA plate reader. 
This ELISA protocol was modified for the following applications: 
Bleeds 
As above except 4) Serum was double diluted in PBS/T and applied (50j.il per 
well) in triplicate. 
Bleed Inhibition 
As above except 4) Serum dilution that gave approx. 20D at 690nm was applied 
(1 00ji1 per well) in triplicate at a range of concentrations of ammonium dansylate. 
Primary Screening 
As above except 4)10-14 d post-fusion 10% complete medium/HAT (100il per 
well) was transfered from fusion plates to dansyl coated plates and incubated at 
room temperature for 4 h. 
Secondary Screening 
As above except 4) The day after primary screening, positive wells from the 
primary screen were tested for inhibition by ammonium dansylate. 10% complete 
medium/HT (50p1 per well) was tranfered to dansyl coated plates with ammonium 
dansylate (50tl per well of 100i.M in PBS/T) and incubated at room temperature 
for 4 h. 
Clone Plate Screening 
As above except 4) 10% complete media (100il per well) was transfered from 
clone plates to dansyl coated plates and incubated for 4 h. 
Antibody Titre 
As above except 4) Primary antibody (10041 per well double diluted in PBS/T) 




As above except 4) Primary antibody dilution that gave approx. 2 OD at 690nm 
was applied (100.t1 per well) in triplicate with decreasing concentrations of 
inhibitor to dansyl coated plates and incubated at room temperature overnight. 
Isotyping 
As above except 6) Secondary antibodylHRP specific to the different mouse 
antibody isotypes (1gM, IgGi, IgG2a, IgG2b, IgG3 and K and 2) was applied 
(100t1 per well diluted 1/100 with PBS/T) and incubated at room temperature for 1 
h. 
Dot Blot Protocol 
Oligonucleotide solutions (500n1) were spotted onto nylon membrane and 
allowed to dry. 
The membrane was irradiated at 254nm for 5 in. 
Blocking buffer (20m1) was applied and incubated at room temperature for 30 
in. 
The membrane was washed with PBS/T (5x). 
Primary antibody (20ml diluted to 1/1000 with PBS/T from approx. lmg/ml 
stock) was applied and incubated at room temperature for 3 h. 
Repeated 4). 
Secondary antibody/HRP (20ml diluted 1/1000 with PBS/T) was applied and 
incubated at room temperature for 1 h. 
Repeated 4). 
DAB substrate (lOml) was applied and incubated at room temperature for 30 in. 
This dot blot protocol was modified for protein fixation by using nitrocellulose 
membrane. This only required drying, irradiation being unnecessary. 
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Ammonium Sulphate Precipitation 
Saturated ammonium sulphate, cooled to 4°C was added slowly to an equal volume 
of hybridoma culture media whilst stirring on ice to give a 50% saturated 
ammonium sulphate solution. After 1 h the suspension was spun (8000G, 30m) and 
the supernatant discarded. The pellet was redissolved in a minimum quantity of 
water and dialysed (3x) against PBS/azide (3000m1). 
Protein-AlProtein-G Affinity Chromatography Protocol 
The affinity column was equilibrated with binding buffer (30m1). 
Antibody was applied to the column as hybridoma culture media or post-
ammonium sulphate precipitation. 
The column was extensively washed with binding buffer (50m1). 
Eluting buffer was applied (lOmi) and fractions (2m1) collected with the 
addition of neutralising buffer (200i1). 
The fractions collected were monitored spectrophotometrically at 280nm. 
The peak fractions were pooled and dialysed (3x) against PBS/azide (1000ml). 
The column was washed with binding buffer (30ml) then 20% ethanol (1 Oml) 
and stored in 20% ethanol at 4°C. 
This protocol was used interchangibly for Protein-A and Protein-G affinity 
columns. 
Antibody Storage 
Purified antibody samples were stored for short periods of time (d or weeks) in 
PBS/azide at 4°C. For long periods of time (months) purified antibody samples 
were stored in PBS/azide at -20°C. 
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The Stability of Duplex DNA Containing 3,N4-Etheno-2'-Deoxycytidine (EdC). A UV 
Melting and High Resolution 1H NMR Study 
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The mutagenic lesion 3,N4-etheno-2'-deoxycytidine (cdC) greatly destabilises DNA when paired with each of the natural 
bases although the solution structure of a duplex containing a EC: A pair shows that the lesion does not greatly disrupt 
base pairing in the duplex. 
Vinyl chloride, an established carcinogen in humans,' is 
epoxidised in vivo by cytochrome P-450 enzymes to chloro-
ethylene oxide which rearranges to chloroacetaldehyde.2 Both 
the haloxirane and the haloaldehyde alkylate DNA giving 
both mono and bifunctional adducts3 including 3,N4-etheno-
2'-deoxycytidine (cdC) 1. When single stranded DNA is 
treated with chloroacetaldehyde mutagenesis is almost exclu-
sively at cytosines4 and consists of 80% C-to-T transitions and 
20% C-to-A transversions. Because the DNA polymerase is 
misreading the template at the cC site and there is ambiguity 
as to the inserted base, cC appears to form non-instructional 
lesions.5 Such lesions are either devoid of template activity, as 
is the case with abasic sites, or have their template activity 
blocked by chemical adducts. When a base is incorporated 
opposite such a lesion it is usually found to be adenine with a 
lower incidence of thymine.6 Non-instructional lesions block 
DNA replication and are lethal unless they are excised from 
the template or bypassed by the replication enzymes. Accord-
ing to the SOS hypothesis,7 arrest of DNA synthesis by 
non-instructional lesions causes induction of the SOS regulon 
and the induced enzymes facilitate DNA synthesis beyond the 
lesion site by an unknown mechanism. However it has been 
observed that mutagenesis by cdC is SOS independent and 
highly efficient and that transfection of Escherichia coli with 
coliphage M13AB28 bearing a single cdC residue does not 
lead to a diminution of the survival of M13 DNA.8 These are 
characteristics of a mispairing lesion. Such lesions contain 
template information which can be decoded by a DNA 
polymerase. However the information is incorrect and leads to 
the misincorporation of a base opposite the lesion without 
impairing DNA replication or cell survival. 
In order to investigate whether cdC forms instructional or 
non-instructional lesions we have prepared the DNA duplexes 
d5'(GCTGcCGACG)3'1d5'(CGTCYCAGC)3', where Y = 
A, G, T or C, which contain cdC paired with each of the four 
natural bases and examined their stability by UV melting. We 
have also examined the solution structure by high field 'H 
NMR of one of these duplexes, d5'(GCTGcCGACG)3'/ 
d5'(CGTCACAGC)3', which contains an cdC: A pair. 
The DNA synthesis monomer 2, which was prepared from 
2'-deoxycytidine,9 coupled during DNA synthesis with 98.5% 
coupling efficiency. The crude oligonucleotide was purified by 






1 R = R' = 
H Me-/\ 	Me 
2 A = DMTr A' 
	 Me 
The thermal dissociation of duplex DNA into its constituent 
single strands leads to hyperchrornicity. The point of maxi-
mum inflection of a plot of UV absorbency versus temperature 
is defined as the melting temperature 	of the duplex. The 
thermodynamics of DNA duplex formation in the presence of 
a cdC lesion were determined according to the method of 
Gaffney and Jones.'() 
Table I shows that the incorporation of cdC into DNA leads 
to a large drop in the free energy of duplex formation. All four 
pairs to cdC are considerably less stable than the Watson-
Crick C: G and A: T base pairs. These data also indicate that 
for the four cdC-containing duplexes, the pairing of A with 
cdC gives the duplex of greatest stability. However the EC: A 
pair is only very slightly more stable than the cC : 0 pair which 
in turn is slightly more stable than the EC: T pair while the 
differences in the stability of all four EC: Y pairs are not large. 
Consequently it would appear to be unlikely that the cdC 
lesion is instructional since it is observed that DNA poly-
merases pair EdC mainly with adenine but also with thymidine. 
Analysis of the 600 MHz 'H NOESY spectrum at 250 ms 
mixing time of the duplex d5'(GIC2T3G4cC5G6 A7C8G9)3'I 
d5'(C'°G' ITI2CISAI4CISAI6G '7C'8)3' in 99.99% D70 buffer 
containing 10 mmol dm-3 phosphate and 100 mmol dm-3 
sodium chloride at 25 °C reveals that the duplex adopts the B 
conformation. The pattern of cross-peaks between the sugar 
H(1)' resonances and the base H(6) and H(8) resonances 
shows that every residue adopts the anti conformation (Fig. 
1). 
Fig. 2 shows the 600 MHz one-dimensional 'H NMR 
spectrum of the imino protons in 90% H20/10% D20 buffer 
containing 10 mmol dm-3 phosphate and 100 mmol dm-3 
sodium chloride at 18 °C. The H20 signal was supressed with 
presaturation and the imino proton spectrum demonstrates 
the different rates of exchange of these protons with the 
solvent. The resonances were assigned from analysis of the 
two-dimensional 600 MHz 1H NOESY spectrum at 250 ms 
mixing time with presaturation of H20. The thymidine N(3)H 
Table 1 The thermodynamic parameters of hybridisation for four cdC 
containing duplexes and the corresponding duplexes containing 
Watson-Crick base-pairs 5'GCT GXG ACG3'/3'CGA CYC TGC5' 
Trn,.ç AS,/ 
(1 	mol)"/ AH°/ ki moI' AG798! 
X Y °C kJmol' K-' kimol' r AAG2981' 
C G 47.2 -264.77 -0.71 -53.19 0.9965 - 
A T 40.6 -290.70 -0.81 -49.32 0.9958 3.92 
EC A 24.6 -255.03 -0.74 -34.51 0.9971 18.67 
EC G 23.9 -218.79 -0.62 -34.03 0.9985 19.17 
EC T 22.3 -270.81 -0.80 -32.41 0.9992 21.56 
EC C 19.7 -236.19 -0.69 -30.57 0.9972 22.91 
For each duplex the Tina x was determined in triplicate at six 
concentrations between the range 3 and 34 cmol dm-3. r = correlation 
coefficient of straight line plot of lnCr i's 	 (1 mol) = the 
calculated melting temperature of the duplex at a concentration of 1 
imol dm-3. 11 AAG298 = the decrease in the free energy of duplex 
formation between the duplex 5'GCT GXG ACG3'/3'CGA CYC 
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I 	I I 	 I 	 I I 	 I 	 I I 
A'H(fl-C'H(6) 
I 	I 
8.2 8.1 8.0 7.9 7.8 7.7 7.6 7.5 7.4 7.3 7.2 7.1 7.0 
F2/ppm 
Fig. 1 Detail of the 600 MHz 1H NOESY spectrum of the duplex 5'd(G1 C2T3G4eC5G6A7C8G9)3'/d5'(ClOGUTl2CI3Al4Gl5Al6Gl7C 8)3' in 
99.99% D20 at 25 °C with 250 ms mixing time showing the connectivities between sugar 1-1(1)' and base 1-1(6)IH(8) resonances and highlighting the 
connectivities from G'H(8) to G9H(1') 
I 	I 	I 	I 	I 	I 	I 	1 	I 
14.0 13.8 13.6 13.4 13.2 13.0 12.8 12.6 12.4 
6 
Fig. 2 Portion of the 60) MHz Il-I  NMR spectrum of the 
duplex 5'd(GIC2T3G4cC5G6A7C8G9)3'/d5'(CI°GIITI2CI3AI4GI5AI6 
GI 7CI8)3' in 90% H20 at 18 °C showing the imino resonances 
signals were assigned by observing an NOE to the correspond-
ing cross-strand deoxyadenosine H(2) signals. The deoxy-
guanosine N(1)H signals were observed to give NOEs to both 
amino signals of the corresponding cross strand deoxycyti-
dine, in turn these amino signals showed NOEs to the H(5) of 
the same base. Thus a chain of assignment could be traced 
from each deoxycytidine H(5) signal to the corresponding 
cross strand deoxyguanosine N(1)H. Of the six possible 
resonances potentially observable in this region (terminal 
imino protons are in fast exchange with the solvent) all are 
seen. It is noteworthy that T12N(3)H, which is remote from 
the lesion site, is in faster exchange with the solvent than both 
the G6N(1)H and G4N(1)H which flank the lesion site and this 
suggests that the T12 A7 base pair is slightly melted out. The 
non-diminution of the G6N(1)H and G4N(1)H signals com-
pared to G'7N(1)H and G' 'N(l)H shows that the C: G base 
pairs on either side of the cC: A base pair are intact and that 
there is no melting of the central region of the duplex around 
the cC lesion. This shows that the instability of duplex DNA 
containing the EC lesion, as shown by UV melting, is not due 
to major disruption of base pairs flanking the lesion site. 
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